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From Bench To Bedside And Back Again: Car T Cell Signaling And Survival
Abstract
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingly
successful in driving cancer remissions. However, early loss of CAR T cells and return of normal B cells is
a predictor of relapse in pediatric acute lymphoblastic leukemia; the duration of remission is associated
with the persistence of CAR T cells for more than three months. These CAR T cells are the product of over
30 years of research and innovation in T cell biology and engineering, which began with the desire to
understand how the T cell receptor (TCR) activates T cells in response to antigen. In this thesis, we return
to that approach again, but this time to investigate signaling downstream of the costimulatory receptor,
4-1BB, a TNF Receptor Superfamily (TNFRSF) member. 4-1BB-costimulated CAR (BBz) T cells exhibit
longer persistence following adoptive transfer than CD28-costimulated CAR (28z) T cells, which contain
the first costimulatory domain commonly added to CARs. 4-1BB signaling improves T cell persistence
even in the context of 28z CAR activation, which indicates that the 4-1BB cytoplasmic domain contributes
unique pro-survival signals. In order to specifically study CAR signaling, we developed a cell-free ligandbased activation and ex vivo culture system for CD19-specific CAR T cells. In this system, we observed
greater ex vivo expansion and survival of BBz CAR T cells compared to 28z T cells. We used this system
to isolate a pathway activated most by BBz CARs, the non-canonical NF-kB (ncNF-kB) pathway, which is
associated with the survival benefit from imparted by other TNFRSFs. We observed that BBz CARs
uniquely activate non-canonical NF-kB (ncNF- kB) signaling in T cells basally, and the anti-CD19 BBz CAR
further enhances ncNF-kB signaling following ligand engagement. Reducing ncNF-kB signaling
specifically diminishes anti-CD19 BBz T cell expansion and survival and is associated with a significant
increase in expression of the most pro-apoptotic isoforms of Bim. Although our findings do not exclude
the importance of other signaling differences between these CARs, they demonstrate the necessary and
non-redundant role of ncNF-kB signaling in promoting BBz CAR T cell survival that likely underlies the
engraftment persistence observed with this CAR design.
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ABSTRACT
FROM BENCH TO BEDSIDE AND BACK AGAIN: CAR T CELL SIGNALING AND
SURVIVAL
Benjamin Philipson
Michael Milone
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies
have been astonishingly successful in driving cancer remissions. However, early loss of
CAR T cells and return of normal B cells is a predictor of relapse in pediatric acute
lymphoblastic leukemia; the duration of remission is associated with the persistence of
CAR T cells for more than three months. These CAR T cells are the product of over 30
years of research and innovation in T cell biology and engineering, which began with the
desire to understand how the T cell receptor (TCR) activates T cells in response to
antigen. In this thesis, we return to that approach again, but this time to investigate
signaling downstream of the costimulatory receptor, 4-1BB, a TNF Receptor Superfamily
(TNFRSF) member. 4-1BB-costimulated CAR (BBz) T cells exhibit longer persistence
following adoptive transfer than CD28-costimulated CAR (28z) T cells, which contain
the first costimulatory domain commonly added to CARs. 4-1BB signaling improves T
cell persistence even in the context of 28z CAR activation, which indicates that the 41BB cytoplasmic domain contributes unique pro-survival signals. In order to specifically
study CAR signaling, we developed a cell-free ligand-based activation and ex vivo
culture system for CD19-specific CAR T cells. In this system, we observed greater ex
iii

vivo expansion and survival of BBz CAR T cells compared to 28z T cells. We used this
system to isolate a pathway activated most by BBz CARs, the non-canonical NF-kB
(ncNF-kB) pathway, which is associated with the survival benefit from imparted by other
TNFRSFs. We observed that BBz CARs uniquely activate non-canonical NF-kB (ncNFkB) signaling in T cells basally, and the anti-CD19 BBz CAR further enhances ncNF-kB
signaling following ligand engagement. Reducing ncNF-kB signaling specifically
diminishes anti-CD19 BBz T cell expansion and survival and is associated with a
significant increase in expression of the most pro-apoptotic isoforms of Bim. Although
our findings do not exclude the importance of other signaling differences between these
CARs, they demonstrate the necessary and non-redundant role of ncNF-kB signaling in
promoting BBz CAR T cell survival that likely underlies the engraftment persistence
observed with this CAR design.
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CHAPTER 1 – INTRODUCTION
Chimeric Antigen Receptor (CAR) T cell therapies for resistant acute
lymphoblastic leukemia in children and young adults have been astonishingly successful
in driving cancer remissions. However, the duration of remission is associated with the
persistence of CAR T cells for more than three months; early loss of T cell persistence
and return of normal B cells is a predictor of relapse (Majzner and Mackall, 2019; Maude
et al., 2014). These persistent CAR T cells are the product of over 30 years of research
and innovation in T cell biology and engineering, which, in a way, began with the simple
desire to understand how the T cell receptor (TCR) activates T cells in response to an
antigen (Kuwana et al., 1987). At the same time, physician-scientists were attempting to
harness T cells to treat melanoma patients, but struggled to direct these cells against the
patients’ tumors specifically (Rosenberg et al., 1988). T cells genetically engineered to
express CARs could be specifically directed to activate upon encountering cells coated
with or expressing antigens bound by the CAR, which triggered the CAR T cells to kill
these “targets” and produce pro-inflammatory signals (Hege and Roberts, 1996).
However, these “first generation” CAR T cells generally performed poorly in animal
models and clinical trials. First generation CARs were unable to initiate or sustain enough
T cell activation to produce an effective therapy, and instead made the CAR T cells
anergic (Brocker and Karjalainen, 1995; Majzner and Mackall, 2019). Just as these initial
in vivo studies failed, immunologists discovered that T cells required a second signal to
the one provided by the TCR to fully activate T cells and promote optimal clonal
proliferation (Smith-Garvin et al., 2009). This second signal, termed “costimulation”,
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could be provided by a number of different molecules. As such, a series of “second
generation” CARs were constructed, which incorporated the intracellular domain of
different costimulatory receptors with the z-chain of the TCR that had been used in first
generation CARs (van der Stegen et al., 2015). Second generation CAR T cells with
CD28 or 4-1BB costimulatory domains targeting B cell leukemias succeeded where their
first generation progenitors had failed: first in animal models (Brentjens et al., 2007; Imai
et al., 2004; Kochenderfer et al., 2009; Kowolik et al., 2006; Milone et al., 2009) and then
in the clinic (Ramos et al., 2014). However, sustained remissions in pediatric ALL are
more frequently achieved by 4-1BB-costimulated CAR T cells that remained detectable
in patients for over 3 months (Majzner and Mackall, 2019). In this thesis, we investigate
how the signaling initiated by 4-1BB costimulation enhances CAR T cell survival.
ORIGIN OF CARs
Chimeric antigen receptors, or CARs, are fusion proteins, combining components
of multiple other proteins into a single structure that can bind to a target and activate the
cell in which the CAR is expressed. CARs were initially built to investigate how the T
cell receptor (TCR) upon recognizing its target, known as its antigen, activates a T cell.
The first such investigation was published in 1987 by Yoshikazu Kurosawa and
colleagues at the Institute for Comprehensive Medical Science at Fujita-Gakuen Health
University in Aichi, Japan (Kuwana et al., 1987). At the time, it was already understood
that the TCR only recognized its antigen and triggered T cell activation when that antigen
was presented to it by another protein, the major histocompatibility complex (MHC), on
the surface of an adjacent cell (Schwartz, 1985). This antigen-MHC presentation
2

requirement of the TCR contrasted with how the other component of the adaptive
immune system, the B cell-generated antibody, bound to its antigen without need of other
proteins in spite of structural similarities between it and the TCR (Hedrick et al., 1984).
Kurosawa and colleagues investigated whether a TCR directed to bind an antigen
in the absence of the presentation could activate a T cell. To do so, they created a
blended, or chimeric, antigen receptor by attaching the heavy or light chains of an
antibody targeting phosphorylcholine to the transmembrane and intracellular domains of
the TCR alpha or beta chains (Kuwana et al., 1987). These two TCR chains do not
contain the intracellular domains, known as immunoreceptor tyrosine-based activation
motifs (ITAMs), to activate the T cell, but must associate with the other TCR chains that
do contain ITAMs to achieve T cell activation. Using a T cell line transfected with
combinations of the chimeras that each contained both heavy and light chains, Kurosawa
and colleagues observed that bacteria coated in phosphorylcholine, but not with bacteria
lacking phosphorylcholine, activated the T cells (Kuwana et al., 1987). This observation,
and a similar one of digoxin-targeted CARs activating T cells shortly thereafter (Becker
et al., 1989), demonstrated that these CARs could activate T cells in an antigen-specific
manner, and therefore functionally associate with the other chains of the TCR.
These first CARs were successful in demonstrating that the TCR needs only to be
bound to its target to achieve T cell activation. They also illustrated that T cells not only
responded to the antigens for which their TCRs had been selected during their maturation
process, but could also be directed to respond to an additional antigen of choice. This
second utility was quickly coopted by Zelig Eshhar and his colleagues at the Weizmann
3

Institute in Rehovot, Israel to overcome a challenge encountered by Steven Rosenberg
and his colleagues at the National Cancer Institute in attempting to harness immune cells
to treat cancer (Eshhar et al., 1993; Gross et al., 1989): Finding and growing enough T
cells that activate when exposed to tumor cells to treat patients was nearly impossible for
most cases (Rosenberg et al., 1988; 1985; Topalian et al., 1987). However, when these T
cells were found, their activation resulted in them killing the tumor cells to which they
were reacting (Hellstrom et al., 1968; Hellström et al., 1968; Lotze et al., 1981), and
causing durable remissions in a small number of patients with melanoma (Rosenberg et
al., 2011). Yet, just the observation that human T cells could kill tumor cells was wildly
controversial.
TREATING CANCER USING THE IMMUNE SYSTEM
The motivating idea behind CAR T cell therapy, that the human immune system
fights cancer, seems both relatively new and yet fully accepted, but dates back at least as
far back as the 1890s and only began to gain acceptance in the 1980s. William Coley, a
New York surgeon in the 1890s, noticed anecdotally that patients who developed
transient infections after having tumors removed were more likely remain cancer-free. He
attempted to apply this observation by injecting the area around tumors he had removed
initially with live and then with heat-killed bacteria. Although there is little evidence that
his technique at the time worked, the idea stuck. The observation in 1917 by J.C.
Mottram and Sidney Russ that rats are capable of rejecting rat sarcoma tumors provided
some of the earliest published evidence of immune-mediated rejection of a tumor (J C
Mottram and Sidney Russ, 1917), and attempts to immunize patients to their own tumor,
4

removed, irradiated and reinjected, occurred as early as 1922 (Kellock et al., 1922).
Nevertheless, a review was published seven years later, now quoted repeatedly, stating
“It would be as difficult to reject the right ear and leave the left ear intact as it is to
immunize against cancer.” (Rosenberg, 1999; Woglom, 1929).
Ultimately, research on bone marrow transplants would provide the strongest
evidence that human immune cells were capable of driving cancer into remission. Bone
marrow transplantation initially seemed to solve a problem created by what became a
leading treatment for blood cancers: myeloablative chemotherapy. Doctors attempted to
treat blood cancers using so much chemotherapy that the patient’s own hematopoietic
stem cells, responsible for creating their immune cells and red blood cells, died. To
rescue the patient from bone marrow failure, physicians transplanted healthy bone
marrow from a donor to replace the marrow that had been destroyed by the
chemotherapy. This strategy was validated by early studies of bone marrow
transplantation in mice that demonstrated that bone marrow from a genetically identical
mouse could be used to repopulate the full repertoire of cells of the blood (Barnes et al.,
1956). Intriguingly, marrow from donor mice that was exposed to a tumor and then
transplanted into recipient mice was more successful in maintaining the recipient mice
cancer-free than marrow from an unexposed donor (Barnes and Loutit, 1957). Yet, nearly
twenty years later, an analysis of allogeneic bone marrow transplantation in 1975
concluded that “the data on allogeneic marrow transplantation for hematologic neoplasia
permit no conclusion about the existence or absence of an antileukemic effect of graftversus-host disease…” (Thomas et al., 1975). The therapeutic failure of marrow depleted
5

of T cells to prevent a potentially deadly side-effect of bone marrow transplants attacking
the recipient, graft-versus-host disease, firmly demonstrated that successful bone marrow
cancer treatment required T cells (Goldman et al., 1988).
DEVELOPING CAR T CELL THERAPIES FOR CANCER
Returning to Rosenberg’s challenge, Eshhar and his colleagues rapidly developed
a set of CARs to direct T cells to kill tumor cells in vitro. T cells were first targeted to
antigens coated onto tumors using CARs comprised of two separate molecules, the TCR
a and b chains each fused to the heavy or light chain of an antibody variable region
(Gross et al., 1989). CARs were then combined into a single molecule by two different
groups, who both fused the extracellular domains of T cell co-receptors to the
transmembrane and intracellular domains of ITAM-containing immunoreceptors, the
CD3z chain (Irving and Weiss, 1991; Romeo and Seed, 1991), or the Fcg chain (Romeo
and Seed, 1991). To maintain the single-chain structure but retain the targeting
demonstrated by the combined heavy and light chain antibody fragment approach, the
heavy and light chains were connected by a linker, creating a single-chain variable
fragment (scFv). This scFv was then fused to either the z- or g-chain to create the first
single molecule CAR targeting cancer cells coated with an antigen (Eshhar et al., 1993).
Eshhar and his team would go on to publish not one, but two functional “first generation”
CARs directed towards two different antigens expressed natively on the tumor cells, the
alpha-folate receptor and Her2 [ERBB2] (Hwu et al., 1993; Stancovski et al., 1993). Yet,
as effective as these early CAR T cells were at killing tumor cells in vitro, these results
were not readily recapitulated in animal models.
6

The next step in translating what started as a laboratory tool to a cancer therapy
was to use these “first generation” CAR T cells to eradicate tumors in mice.
Unfortunately, multiple groups found that their success in vitro did not lead to tumor
clearance in vivo (Hwu et al., 1995; Moritz et al., 1994). These early failures in mouse
models with “first generation” CARs would ultimately prove predictive of human clinical
trials (Deeks et al., 2002; Kershaw et al., 2006; Park et al., 2007; Till et al., 2008) despite
contradictory evidence from a report using a z-chain CAR targeting ERBB2 in a mouse
breast cancer model (Altenschmidt et al., 1997), and another demonstrating that a z-chain
CAR was superior to a g-chain CAR in a colon cancer model (Haynes et al., 2001). One
possible explanation for these failures was a z-chain CAR alone was inadequate to
activate T cells without those T cells having been previously activated (Brocker and
Karjalainen, 1995), like the TCR from which the CAR signaling domain was derived
(Harding et al., 1992; Tan et al., 1993).
SECOND GENERATION CARs: ADDING COSTIMULATION
The missing ingredient to achieve T cell activation was costimulation. Initially,
costimulation was found to be provided to previously unstimulated T cells by the
immunoglobulin superfamily member, CD28 (Harding et al., 1992; June et al., 1987; Tan
et al., 1993). When CD28 bound to its ligands, CD80 or CD86, in the absence of TCR
activation, T cells did not activate. However, simultaneous TCR and CD28 ligand
binding drove robust T cell activation. Because CD28 ligand binding had no effect on its
own, this cooperative phenomenon was called “costimulation.”
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To incorporate costimulation into CARs, CD28 was combined with activation
from an ITAM-containing receptor in T cells initially as two separate molecules: an scFv
fused to the transmembrane and intracellular domains of CD28 (Krause et al., 1998)
alone, or co-expressed with a z-chain CAR (Alvarez-Vallina and Hawkins, 1996). The
first single molecule with CD28, the z-chain, and a single scFv targeted CD33, a protein
expressed on acute myeloid leukemia cells, and only demonstrated an improvement over
the z-chain-only CAR in IL-2 secretion, the growth factor that Rosenberg had used to
expand the tumor-reactive T cells from his melanoma patients (Finney et al., 1998). Yet,
this single reported enhancement triggered a new race to build costimulated “second
generation” CARs that would succeed where “first generation” CARs had failed, in vivo.
Most groups constructed CARs that employed the CD28 costimulatory domain in
a second-generation design and targeted antigens on solid tumors (Hombach et al., 2001;
Maher et al., 2002; van der Stegen et al., 2015). Bucking both trends and drawing upon
the lessons of bone marrow transplant for treating leukemia, Michael Jensen’s group at
the City of Hope Medical Center and the Fred Hutchinson Cancer Research Center
postulated that directing T cells specifically to leukemia cells would be a potent
technique, but would spare the patient the toxicities of graft-versus-host-disease (Cooper
et al., 2003). Jensen and colleagues created a “first generation” CAR targeted to CD19, a
universal B cell marker and one present on nearly all leukemia cells originating from B
cells (Cooper et al., 2003). These human anti-CD19 CAR T cells efficiently killed CD19expressing leukemia cells in culture. As was the case with all previous “first generation”
CARs, this CAR would be replaced with more effective “second generation” CARs
8

(Brentjens et al., 2007; Imai et al., 2004; Kochenderfer et al., 2009; Kowolik et al., 2006;
Milone et al., 2009).
Unlike the initial trend in “second generation” CAR development, two of these
groups incorporated 4-1BB, a Tumor Necrosis Factor Receptor Superfamily (TNFRSF)
member, instead of CD28 in their anti-CD19 CARs (Imai et al., 2004; Milone et al.,
2009). 4-1BB can substitute for CD28 costimulation in T cells (DeBenedette et al., 1997;
Saoulli et al., 1998), limit T cell death from activation (Hernandez-Chacon et al., 2011)
and was found to be critical for cytotoxic T cell memory (Wang et al., 2009). Dario
Campana and his team at the St. Jude Children’s Research Hospital in Memphis,
Tennessee, demonstrated that a CD19-specific CAR constructed with the 4-1BB
cytoplasmic domain were better killers of leukemia cell blasts than those without 4-1BB
(Imai et al., 2004). The group of investigators lead by Carl June at the University of
Pennsylvania incorporated this CAR into an optimized lentiviral vector transduction
system and combined it with a well-established microbead-based human T cell
manufacturing platform developed in HIV-targeted CAR T cell trials (Levine et al., 1998)
born out of the early work done to combine the CD4 coreceptor with the z-chain (Romeo
and Seed, 1991). This work demonstrated that manufactured human anti-CD19 4-1BB
costimulated CAR-T cells are more effective than their CD28-costimulated counterparts
in immunocompromised mouse models of human primary acute lymphoblastic leukemia
(Milone et al., 2009). Armed with this improved “second generation” CAR, the antiCD19 4-1BB CAR-T cell therapy was launched into the clinic.
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immunotherapy, the June group published the results of a small pilot trial using antiCD19 4-1BB costimulated CAR T cell therapy to treat three patients with the chronic
lymphocytic leukemia (Porter et al., 2011). Surpassing all expectations, all three patients
experienced complete remissions. This first success was followed by an expanding
cascade of trials using either CD28 or 4-1BB costimulated anti-CD19 CAR T cells to
treat B cell leukemias (Maude et al., 2018; Neelapu et al., 2017; Ramos et al., 2014),
which resulted in the first FDA approvals of CAR T cell therapies for CD19-positive B
cell malignancies: first for 4-1BB costimulated CAR T cell treatment of pediatric and
young adult ALL (O'Leary et al., 2019), and then for CD28 costimualted CAR T cell
treatment of adult diffuse large B cell lymphoma (Bouchkouj et al., 2019). From these
trials, specifically those in pediatric and young adult ALL, an important pair of patterns
emerged: Durable remissions were sustained when CAR T cells persisted for many
months in patients (Mueller et al., 2018), and the most persistent CAR T cells were those
with 4-1BB costimulation (Majzner and Mackall, 2019).
However, comparing the results of these trials is difficult as there are multiple
differences between the CAR T cells used in these trials, including different antibody
single-chain variable fragments, vector backbones used to transduce the T cells with
CAR DNA, and culture methods to expand the CAR T cells prior to treatment (Barrett et
al., 2014; Maude and Barrett, 2016; Miller and Rosman, 1989; Naldini et al., 1996). Two
preclinical studies directly comparing CD28 and 4-1BB costimulated CARs, one using
retroviral transduction (Long et al., 2015) and the other using lentiviral transduction
10

(Wang et al., 2015), both showed that 4-1BB costimulated CAR T cells persist longer
than their CD28 costimulated counterparts. To compare the impact of CAR-mediated
CD28 and 4-1BB costimulation on CAR T cell proliferation and survival in the absence
of initial T cell receptor and CD28 stimulation, our group used RNA electroporation to
transiently express anti-CD19 z-chain-based CARs with either CD28 or 4-1BB
costimulatory domains in human T cells and stimulated these T cells with CD19 target
beads (Kawalekar et al., 2016). Our group found that 4-1BB costimulated RNA CAR T
cells proliferated and survived longer in vitro than their CD28 costimulated counterparts.
In addition, more 4-1BB costimulated RNA CAR T cells expressed surface markers of T
cell memory and had greater spare respiratory capacity, mitochondrial mass, and higher
levels of the master regulator of mitochondrial biogenesis, TFAM than their CD28
costimulated counterparts (Kawalekar et al., 2016). This additional spare respiratory
capacity likely underlies the proliferative and persistence advantage of memory T cells
over effector T cells used in a murine model of adoptive T cell cancer therapy (van der
Windt et al., 2013). These studies identified the CAR costimulatory domain as a key
determinant of CAR T cell survival, but the mechanisms by which CAR CD28 and 41BB costimulation mediated this effect remained unknown.
COMPARING CD28 AND 4-1BB SIGNALING
Most of what is known about these domains comes from studying them in their
endogenous forms. They are members of two distinct families of receptors; CD28 is a
member of the immunoglobulin superfamily (Aruffo and Seed, 1987), and 4-1BB
belongs to the Tumor Necrosis Factor Receptor Superfamily (Smith et al., 1990). CD28 is
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expressed on quiescent “naive” T cells (Rudd et al., 2009), whereas 4-1BB is only
expressed on activated T cells (Pollok et al., 1993). They use entirely distinct
mechanisms to activate downstream signaling. CD28 has a series of motifs that directly
recruit downstream signaling molecules upon receptor ligation and phosphorylation of
some of these motifs (Boomer and Green, 2010). In contrast, 4-1BB signals through the
recruitment of distinct multimers of TNF Receptor Associated Factors (TRAFs) when
quiescent or upon ligand binding (Zapata et al., 2018). Despite all of these differences, 41BB activation can substitute for CD28 in CD28 KO T cells (DeBenedette et al., 1997).
As such, one might expect that both receptors signal through largely overlapping
downstream pathways.
CD28 signaling is functionally similar to that of the antigen-MHC-bound TCR
complex. Like the T cell coreceptors, CD4 and CD8, CD28 directly associates with Lck
(Holdorf et al., 1999; King et al., 1997), which is responsible for phosphorylating the
tyrosines in the ITAMs of the TCR complex and the activating tyrosines in ZAP-70 (Bu
et al., 1995; Chan et al., 1995; Pitcher and van Oers, 2003), the pivotal kinase involved in
transducing ITAM-mediated signaling in T cells (Chan et al., 1992). Upon binding either
of its ligands, CD80 or CD86, CD28 also functionally mimics LAT, an adaptor recruited
to the TCR complex, by recruiting PI3K (Pagès et al., 1994; Prasad et al., 1994), which
drives AKT, mTOR, and canonical NF-kB signaling (Hemmings and Restuccia, 2012),
and GRB2 (Kim et al., 1998; Schneider et al., 1995), which, through Ras, activates ERK
and p38 MAPK (Boomer and Green, 2010). Potentiation of these pathways enhances IL2 production (Thomas et al., 2005), increases anti-apoptotic protein Bcl-XL expression
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(Boise et al., 1995), and prolongs T cell survival (Jones et al., 2002). However,
endogenous CD28 lacks an ITAM, and therefore cannot recruit ZAP-70 or initiate T cell
activation alone (June et al., 1990). These signaling pathways are depicted in Figure 1.1.
Upon CD28 activation in conjunction with TCR ligand-binding, CD28 is trafficked away
from the ITAM-containing subunits of the CD3 complex (Bashour et al., 2014).
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Figure 1.1: TCR and CD28 Signaling Pathways. A Cartoon graphic of an idealized
interaction between an antigen presenting cell (APC) and a T cell. The TCR complex
is shown on the right, binding to an antigen-MHCI complex. CD8 is recruited and
binds the CD3-MHC complex, bringing Lck along with it. Lck phosphorylates ITAMs
on CD3 (those of CD3z are specifically highlighted here). These phospho-ITAMs
serve as a binding site for ZAP-70, which is also phosphorylated by Lck. CD28, on
the right, engages its ligand, CD80. This interaction triggers phosphorylation of its
membrane-proximal YMNM-motif, which recruits PI3K and GRB2. These two
molecules then activate downstream signaling, of which mTOR, canonical NF-kB,
ERK and p38 MAPK are highlighted here. Those downstream signals of interest
shared with 4-1BB are highlighted.

Like CD28, 4-1BB must bind its own ligand, 4-1BBL, in the context of TCR
antigen binding to impact T cell activation (Saoulli et al., 1998). 4-1BB is expressed as
either a monomer or a dimer upon T cell activation (Pollok et al., 1993) and basally
associates with TRAFs 2 and 3 (Arch and Thompson, 1998), the latter of which acts as a
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negative regulator (Takaori-Kondo et al., 2000). Upon trimerization by binding 4-1BBL
(Bitra et al., 2018; Gilbreth et al., 2018a; Won et al., 2010), 4-1BB recruits TRAF1 (Arch
and Thompson, 1998), and together with TRAF2, induces ubiquitin-mediated degradation
of TRAF3 (Jang et al., 1998; McPherson et al., 2012). TRAF3 degradation combined
with TRAF1 recruitment causes the initiation of downstream signaling by ERK activation
(Sabbagh et al., 2008) through LSP1 (Sabbagh et al., 2013), canonical NF-kB signaling
(Arch and Thompson, 1998) through TBK1 phosphorylation of IKKa/b (Oussa et al.,
2013), and p38 MAPK through ASK1 (Cannons et al., 2000; Menk et al., 2018) (Figure
1.2). Though the intermediates are different, endogenous 4-1BB signaling largely appears
to overlap with signaling driven by CD28.
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Figure 1.2: TCR and 4-1BB Signaling Pathways. A Cartoon graphic of an idealized
interaction between an activated antigen presenting cell (APC) and an activated T cell.
The TCR complex is shown on the right, as in Figure 1.1. 4-1BB, on the right,
engages its ligand, 4-1BBL. This interaction triggers trimerization and recruitment of
TRAFs 1 and 2, which induce the degradation of the negative regulator, TRAF3.
TRAFs 1 and 2 then activate downstream signaling, of which ERK, canonical NF-kB,
and p38 MAPK are highlighted here. Those downstream signals of interest shared
with CD28 are highlighted.

Studies exploring CAR costimulatory domain signaling have been somewhat
limited, but have generally recapitulated this overlap. The broadest comparison between
anti-CD19 CD28 and 4-1BB costimulated CAR signaling was recently published by
Stanley Riddell and his colleagues at the Fred Hutchison Cancer Research Center in
Seattle, WA (Salter et al., 2018). Using activated T cells expressing anti-CD19 CD28 or
4-1BB costimulated CARs and beads coated with antibodies against an ST2 tag within
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the CARs, these investigators assessed phosphorylation of numerous proteins by mass
spectrometry 15 minutes and 45 minutes after CAR activation. This unbiased approach
confirmed the overlap in phosphorylation targets between the CD28 and 4-1BB
costimulated CARs, but also revealed that the CD28 CAR drives greater phosphorylation
of these targets in this timeframe. These findings may partially explain how CD28
costimulated CAR T cells become more glycolytic than 4-1BB costimulated CAR T cells
(Kawalekar et al., 2016), as this is a feature of CD28 costimulation (Frauwirth et al.,
2002). They may also explain why limiting the ITAMs on the CAR z-chain improves
CAR T cell survival (Feucht et al., 2019), as this strategy may mimic the diminished the
downstream signaling of the 4-1BB costimulated CAR. However, if this kinetic and
quantitative signaling difference were the only one between these costimulatory domains,
adding 4-1BB costimulation to that provided by CD28 should be lost in the noise of the
CD28 signal. Yet, when CD28 CAR T cells are costimulated separately by 4-1BB, such
as by 4-1BBL expression to activate endogenous 4-1BB, those CAR T cells have
enhanced survival and persistence (Drent et al., 2019; Zhao et al., 2015).
The major hypothesis of my thesis is that the enhanced persistence observed
with 4-1BB-costimulated CAR T cells is supported by induction of the noncanonical NF-kB signaling pathway. This unique NF-kB pathway is activated by
different TNFRSFs, but not CD28, and is important for promoting cell survival in a
variety of cell contexts (Coope et al., 2002; Hauer et al., 2005; Li et al., 2005; Marinari
et al., 2004; Müller and Siebenlist, 2003; Sun, 2017).
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Nuclear Factor k-light-chain-enhancer of activated B cells (NF-kB) signaling is
sometimes erroneously described as a single pathway that marks active inflammation (Li
et al., 2018), but is comprised of five different proteins that act as transcription factors by
combining in various dimer pairs that induce distinct changes in transcription (Figure 1.3)
(Sun, 2017). RelA, also known as p65, and the active form of p105, p50, form what is
known as the canonical dimer, and translocate to the nucleus following activating signals
from a wide variety of stimuli including activation of the TCR (Pitcher and van Oers,
2003), CD28 (Kane et al., 2002), and 4-1BB (McPherson et al., 2012), along with
numerous cytokine receptors (Vallabhapurapu and Karin, 2009). Both CD28 and 4-1BB
costimulated CARs have been reported to activate canonical NF-kB signaling, but these
reports conflict in the relative importance of canonical NF-kB signaling to the function of
each CAR (Carpenito et al., 2009; Li et al., 2018). Intriguingly, the CD28 and 4-1BB
costimulatory domains activate the canonical NF-kB pathway through different proximal
signaling intermediates. CD28 does so by activating PKCq whereas 4-1BB does so by
activating TGFb-activated kinase 1. These signals converge to activate the canonical NFkB pathway by inducing the Inhibitor of kB kinases (IKKs) a, b, and g, to trimerize and
phosphorylate Inhibitor of kBs (IkBs), which, when unphosphorylated, bind p65/p50
dimers and localize them to the cytoplasm. Phosphorylated IkBs are rapidly degraded by
the proteasome, allowing p65/p50 dimers to translocate to the nucleus and alter gene
regulation. This activation is often short-lived, as p65/p50 dimers increase transcription
of IkBs that remove the dimers from the nucleus (Mukherjee et al., 2017; Sun et al.,
1994).
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CD28
Cytokine
Receptors

TNFRSFs

Figure 1.3: The canonical (classical) and non-canonical (alternative) NF-kB
pathways. A Cartoon graphic of multiple surface receptor-mediated pathways to
initiate canonical or non-canonical NF-kB signaling. The canonical pathway, shown in
the center, can be activated by a number of receptors (as shown here) and intracellular
stress signals (not depicted). The canonical pathway converges on the IKKa, b, g
complex, which phosphorylates IkBs. Phospho-IkBs are degraded, allowing the
canonical dimer, p65/p50, to enter the nucleus. In contrast, only certain TNFRSFs can
activate the non-canonical pathway, shown on the right. This pathway is triggered by
the stabilization of the NF-kB-inducing kinase (NIK), which phosphorylates IKKa.
IKKa can then phosphorylate p100, creating a phosphodegron. This portion of p100 is
degraded, leaving the active form, p52, to enter the nucleus in the non-canonical
dimer, RelB/p52. Adapted from Mortier, J., et al., 2010.

Unlike the canonical pathway, the non-canonical NF-kB dimer, RelB/p52, only
translocates to the nucleus upon activation of certain TNFRSFs and viral proteins and has
not yet been studied downstream of CAR activation (Sun, 2017). Non-canonical NF-kB
signaling begins with the stabilization of NF-kB Inducing Kinase (NIK) (Malinin et al.,
1997; Xiao et al., 2001), which TRAF3 basally targets to cIAP1 and 2 (Liao et al., 2004;
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Zarnegar et al., 2008). These E3 ubiquitin ligases K48-polyubiqutinate NIK, which is
subsequently degraded by the proteasome (Zarnegar et al., 2008). Murine 4-1BBmediated activation coordinates TRAFs 1 and 2 to shift cIAP1/2-mediated K48
polyubiquitination from NIK to TRAF3, thereby alleviating NIK K48 polyubiquitinationmediated degradation (Jang et al., 1998; McPherson et al., 2012; Saoulli et al., 1998;
Vallabhapurapu et al., 2008; Zarnegar et al., 2008). As NIK slowly accumulates in the
cytoplasm, it phosphorylates IKKα (Ling et al., 1998) and coordinates a complex
including IKKα and the NF-kB family member p100 (Xiao et al., 2001). IKKα
phosphorylates p100 (Senftleben et al., 2001), creating a phosphodegron to be K48polyubiquitinated and partially degraded by the proteasome, forming p52 (Xiao et al.,
2001). Prior to NIK and IKKα activation, p100 basally sequesters RelB, another Rel
homology domain family member, in the cytoplasm. Upon p100 processing to p52, RelB
and p52 translocate to the nucleus as a heterodimer (Claudio et al., 2002). Therefore,
p100 processing and RelB/p52 dimer nuclear translocation are the hallmarks of noncanonical NF-kB activation (Fig. 1.4).
Both canonical and non-canonical NF-kB signaling drive T cell survival, albeit in
opposite ways. P65/p50 dimers activate transcription of the Bcl-2 anti-apoptotic protein
family member, Bcl-xL, which supports survival of both CD28 and 4-1BB costimulated
T cells (Khoshnan et al., 2000; Stärck et al., 2005). In contrast, RelB/p52 dimers inhibit
expression of pro-apoptotic proteins Bim and BMF (Vallabhapurapu et al., 2015; Wang
et al., 2008). Bim and BMF are also members of the Bcl-2 family, but unlike the antiapoptotic members of this family, Bim and BMF are part of the BH3-only subfamily
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(O'Connor et al., 1998). BH3-only Bcl-2 family members promote apoptosis by binding
anti-apoptotic Bcl-2 family members, thereby preventing them from inhibiting the
formation of the apoptotic pore on the surface of the mitochondria (Hockings et al.,
2018). Once this pore is opened, cytochrome c escapes from the mitochondrial matrix
and triggers apoptosis (McArthur et al., 2018) (Figure 1.4). As such, the expression of
Bim and its fellow BH3-only family members is tightly regulated (Puthalakath and
Strasser, 2002). Unregulated Bim suppression by constitutive p52 expression causes a
massive increase in circulating T cells and results in mutli-organ autoimmunty (Wang et
al., 2008). Conversely, T cells with homozygous inactivating mutations in p100,
preventing p100 processing to p52, were unable to induce experimental autoimmune
encephalitis, a T cell-mediated murine autoimmune disease (Yu et al., 2014).
Furthermore, T cells from NIK knockout mice form few persistent memory cells when
initially challenged with acute LCMV infection (Rowe et al., 2013). T cell-specific NIK
knockout mice have substantially fewer circulating memory T cells than WT controls (Li
et al., 2016).
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Figure 1.4: Bcl-2 Protein Family Regulation of Innate Apoptosis Pathway. A
Cartoon graphic of the mitochondrial double membrane depicting the regulation of
apoptotic pore formation. Anti-apoptotic Bcl-2 family members, represented by the
green Bcl-xL/Bcl-2, prevent formation of the pore by binding with the pore-forming
proteins Bax and Bak, shown in red on the right. On the left, Bim, representing BH3only proteins, can interfere with the Bcl-xL-Bax interaction by binding Bcl-xL (or
other Bcl-2 family members) and allow the pore to form. This pore facilitates
cytochrome c translocation to the cytoplasm, where it initiates apoptosis.

The loss of surviving memory T cells is notable, as T cell phenotype strongly
impacts T cell antitumor activity (Fraietta et al., 2018; Ghassemi et al., 2018; Klebanoff
et al., 2005; Sommermeyer et al., 2016). The phenotype of a mature T cell is influenced
by a number of factors, but generally reflects whether or not that T cell has encountered
its antigen, and its capacity for future expansion (Gattinoni et al., 2011; Sallusto et al.,
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2004). Naïve T cells, as their name suggests, are unlikely to have encountered their
antigen before. They have a high proliferative potential and metabolically favor oxidative
phosphorylation, but are slow to begin dividing upon activation (Kaech and Ahmed,
2001). Effector T cells have encountered their antigen and become metabolically
glycolytic (MacIver et al., 2013). They express proteins enabling them to kill target cells,
such as granzyme B and perforin, and inflammatory cytokines, but have little to no
proliferative potential (Sallusto et al., 2004). Finally, memory T cells, and specifically
stem cell memory T cells, are T cells that have encountered their antigen, but unlike
effector T cells, have a large proliferative potential, and unlike naïve T cells, can
proliferate rapidly upon antigen stimulation (Gubser et al., 2013; Sallusto et al., 2004;
van der Windt et al., 2013). Memory CAR T cells tend to have the greatest antitumor
efficacy (Ghassemi et al., 2018; Sommermeyer et al., 2016), and the presence of stem cell
memory T cells in the CAR T cell products made from CLL patients’ T cells correlated
with long term remission (Fraietta et al., 2018).
Memory T cells also require oxidative metabolism to develop, function and
rapidly proliferate (Pearce et al., 2009; van der Windt et al., 2013; 2012). Memory T cells
basally consume more oxygen to make ATP and have a substantially greater spare
respiratory capacity, the difference between maximal oxygen consumption elicited by the
proton ionophore FCCP and basal oxygen consumption, than effector T cells (van der
Windt et al., 2012). Memory T cell spare respiratory capacity is driven by fatty acid
oxidation (van der Windt et al., 2012), which, when upregulated, can enhance memory T
cell proliferation after restimulation (Pearce et al., 2009). Critically, this rapid memory T
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cell proliferation following restimulation requires substantial mitochondrial mass and
spare respiratory capacity (van der Windt et al., 2013). Mitochondrial biogenesis and
spare respiratory capacity have been shown to be increased by activation of the noncanonical NF-kB pathway in both osteoclasts and skeletal muscle fibers (Bakkar et al.,
2012; Zeng et al., 2015). In both cell types, RelB/p52 dimers were observed to directly
bind at two sites within the first intron of master mitochondrial biogenesis regulator, pgc1b, and increase PGC-1b expression. PGC-1b expression was diminished by RelB
knockout in the osteoclasts (Zeng et al., 2015) and knockdown in the skeletal muscle
fibers (Bakkar et al., 2012). Critically, PGC-1b expression correlated with mitochondrial
mass and oxygen consumption rate in both cell types (Bakkar et al., 2012; Zeng et al.,
2015). The increase in oxygen consumption rate and mitochondrial mass observed in
these cell types resembles that observed in 4-1BB costimulated CAR T cells (Kawalekar
et al., 2016).
Endogenous 4-1BB costimulation also directly promotes T cell persistence
through the downregulation of Bim (Sabbagh et al., 2008). Bim suppression in T cells by
4-1BB depends upon ERK activation (Sabbagh et al., 2008). In multiple myeloma cells,
ERK activation inhibits transcription of the bcl2l11 locus in cooperation with the noncanonical NF-kB dimer, RelB/p52 (Vallabhapurapu et al., 2015). RelB/p52, together
with phospho-ERK, binds the bcl2l11 promoter and recruits histone deacetylease 4
(HDAC4). HDAC4 deacetylates the surrounding histones, thereby closing the locus and
rendering it inaccessible to RNA polymerases (Vallabhapurapu et al., 2015). When Bim
is transcribed and translated, it plays a central role in regulating T cell survival through
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deletion of autoreactive B cell clones (Ludwinski et al., 2009; Wang et al., 2008), and
short-lived effector T cells (Wojciechowski et al., 2006).
Given the specific association between TNFRSFs and the non-canonical NF-kB
pathway, which drives T cell survival, memory T cell-supporting oxidative metabolism,
and suppression of pro-apoptotic protein, Bim, we hypothesized that 4-1BB-costimulated
CARs improve T cell survival by induction of oxidative metabolism and suppression of
Bim by activating the non-canonical NF-kB pathway.
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CHAPTER 2
ABSTRACT
Clinical response to chimeric antigen receptor (CAR) T cell therapy is correlated with
CAR T cell persistence, especially for CAR T cells targeting CD19+ hematologic
malignancies. 4-1BB-costimulated CAR (BBz) T cells exhibit longer persistence
following adoptive transfer than CD28-costimulated CAR (28z) T cells. 4-1BB signaling
improves T cell persistence even in the context of 28z CAR activation, which indicates
that the 4-1BB cytoplasmic domain contributes unique pro-survival signals to T cells. In
order to specifically study the signal transduction by CARs, we developed a cell-free
ligand-based activation and ex vivo culture system for CD19-specific CAR T cells, in
which we observed greater ex vivo expansion and survival of BBz CAR T cells when
compared to 28z T cells. We show that BBz CARs uniquely activate non-canonical NFkB (ncNF-kB) signaling in T cells basally, and the anti-CD19 BBz CAR further
enhances ncNF-kB signaling following ligand engagement. Reducing ncNF-kB signaling
specifically diminishes anti-CD19 BBz T cell expansion and survival and is associated
with a significant increase in expression of the most pro-apoptotic isoforms of Bim.
Although our findings do not exclude the importance of other signaling differences
between BBz and 28z CARs, they demonstrate the necessary and non-redundant role of
ncNF-kB signaling in promoting the survival of BBz CAR T cells that likely underlies
the engraftment persistence observed with this CAR design.
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INTRODUCTION
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has induced
complete tumor regression in a large percentage of patients suffering from hematologic
malignancies, especially in children and young adults with acute lymphoblastic leukemia
(ALL) (Feins et al., 2019). Event-free survival following CD19-specific CAR T cell
therapy is highly correlated with the kinetics of T cell expansion and the area under the
concentration-time curve (AUC) for the first 28 days following adoptive transfer
(Mueller et al., 2018). While antigen or epitope loss remain the most frequent
mechanisms of resistance to this therapy (Orlando et al., 2018), relapse within the first six
months is associated with early loss of CAR T cell engraftment illustrating the
importance of persistent T cell engraftment to the success of adoptive cell therapy
approaches (Mueller et al., 2018; 2017; Turtle et al., 2016).
The persistence of CAR T cells in vivo over time following adoptive transfer is
influenced by CAR design. CARs are transmembrane proteins comprised of an antibody
single-chain variable fragment (scFv), a hinge connecting to a transmembrane domain,
and one or more intracellular signaling domains (van der Stegen et al., 2015). The most
commonly used designs combine the T cell receptor subunit CD3z with the intracellular
domain of either of the co-stimulatory molecules, CD28 or 4-1BB. Comparing CAR T
cell persistence across human clinical trials using 28z or BBz CD19-specific CARs,
although fraught with pitfalls due to the other differences in the CARs used or in T cell
manufacturing (e.g. scFv, gene transfer vector or culture conditions), suggests greater
persistence of 4-1BB-costimulated CAR T cell engraftment relative to CD2827

costimulated CAR T cells (Maude et al., 2018; Neelapu et al., 2017). This trend is more
directly substantiated in murine adoptive transfer models, implying that costimulation
directly impacts CAR T cell persistence (Weinkove et al., 2019). When exchanged with
CD28 costimulation, 4-1BB costimulation also rescues CAR T cell survival in the
context of a basally signaling CAR (Long et al., 2015), and basally signaling BBz CARs
can expand dramatically ex vivo (Frigault et al., 2015).
The signaling pathways that lead to the observed differences in CAR T cell
persistence remain poorly understood. Salter et al. demonstrated that 28z CARs drives
both constitutive and CAR-activation-induced proximal signaling through Lck and Zap70
more potently than the BBz CARs (Salter et al., 2018). This potent proximal signaling
promotes terminal differentiation of 28z CAR T cells, which can be reversed by silencing
two of the ITAM domains of the CD3z domain (Feucht et al., 2019). This reversal
suggests that CD28 signaling in the CAR is a dominant mechanism for this CAR’s
reduced persistence. However, 4-1BB costimulation enhances CAR T cell survival and
persistence even in the context of the full 28z CAR signal (Drent et al., 2019; Zhao et al.,
2015). This enhancement is consistent with the non-overlapping roles that these
costimulatory receptors play in normal immunity, especially for CD8+ T cell memory
(Bertram et al., 2002; Giardino Torchia et al., 2015; Hurtado et al., 1997; Lee et al., 2002;
Shuford et al., 1997). Long-term CD8+ T cell survival following viral infections is
supported by specific Tumor Necrosis Factor Receptor Superfamily members
(TNFRSFs), including 4-1BB (Hendriks et al., 2005; Snell et al., 2011). Unlike CD28, a
unique property of these receptors, and specifically observed in one report on murine 428

1BB, is the capacity to activate the non-canonical NF-kB pathway (ncNF-kB) (Li et al.,
2005; McPherson et al., 2012; Ramakrishnan et al., 2004; Xiao et al., 2016). Distinct
from the classical NF-kB downstream of TCR and CD28 signaling via the CARMA1
complex and PKCq (Kane et al., 2002; Li et al., 2005; Schimmack et al., 2014; Sun et al.,
2000), the ncNF-kB pathway promotes cell survival in numerous contexts including
normal lymphoid development under the control of TNF receptor superfamily members
(Claudio et al., 2002; Shinkura et al., 1999; Willmann et al., 2014), Epstein-Barr virus
infection (Eliopoulos et al., 2003) and malignancy (Cormier et al., 2013; Ranuncolo et
al., 2012; Vallabhapurapu et al., 2015; Wharry et al., 2009).
NcNF-kB signaling is a complex pathway with slower activation kinetics
compared with classical NF-kB. It is initiated by the stabilization of NF-kB-Inducing
Kinase (NIK), which is K48-polyubiqutinated by cIAP1 and 2 and constitutively
degraded by the proteasome (Sun, 2017). Upon TNFRSF trimerization by its ligand,
differential TNF Receptor Associated Factor (TRAF) recruitment shifts cIAP1/2mediated K48 polyubiquitination from NIK to TRAF3, thereby alleviating the continuous
K48 polyubiquitination-mediated degradation of NIK. NIK accumulates and coordinates
a protein complex including Inhibitor of NF-kB Kinase alpha (IKKα), and the Rel
homology domain family members RelB and p100, the latter two of which form a
heterodimer that is basally sequestered in the cytoplasm. Accumulating NIK
phosphorylates IKKα, which in turn phosphorylates p100, creating a phosphodegron that
leads to partial degradation by the proteasome to form p52. The newly formed RelB/p52
heterodimer then translocates to the nucleus where it mediates transcriptional control of
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numerous genes involved in lymphoid development (Sun, 2017), mitochondrial
biogenesis in skeletal muscle and osteoclasts (Bakkar et al., 2012; Zeng et al., 2015), and,
in cancer cells, synergizes with ERK to suppress proapoptotic genes Bim and BMF
(Vallabhapurapu et al., 2015). This complex signaling pathway is illustrated
schematically in Figure 1.3.
Like 4-1BB, ncNF-kB signaling is also essential for T cell immunity. Memory T
cells require ncNF-kB signaling to survive both in mice (Li et al., 2016; Rowe et al.,
2013) and in humans; the latter requirement was revealed by a deficiency of long-lived
memory T cells in two patients with biallelic loss-of-function mutations in NIK
(Willmann et al., 2014). Similarly, mice deficient in NIK form few persistent memory T
cells when challenged with acute LCMV infection (Rowe et al., 2013). This loss was
found to be cell-intrinsic as T cell-specific NIK KO mice have substantially fewer
circulating memory T cells than WT controls (Li et al., 2016).
Based upon the importance of ncNF-kB signaling to T cell memory formation and
the report of activation of this pathway by endogenous 4-1BB in murine T cells, we
evaluated the activation and role of this pathway in human CAR T cells. We show that
ncNF-kB signaling plays an essential role in supporting BBz CAR T cell survival. In
addition to providing greater insight into the costimulatory mechanisms of the CD28 and
4-1BB domains in CARs, the increased understanding of the role of this pathway in
human T cells offers opportunities to manipulate it more broadly in T cell-based
immunotherapies that rely upon T cell survival to mediate clinical benefit.
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RESULTS
4-1BB costimulation enhances ex vivo CAR T cell expansion relative to CD28
costimulation and is associated with improved T cell survival
To study the ex vivo expansion of T cells following stimulation by CD19-specific
CARs bearing different costimulatory domains, we employed the approach of repeated in
vitro stimulation (Drent et al., 2019; Feucht et al., 2019; Milone et al., 2009; Zhao et al.,
2015). We added irradiated Nalm6 leukemic cells bearing the CD19 target antigen to
mCherry-expressing 28z or BBz CAR T cell cultures (Figure 2.1A) at 7-day intervals as
shown in a representative growth curve in Figure 2.1B. Similar to prior studies
comparing CD28 and 4-1BB (CD137) costimulated CARs, T cells bearing a 4-1BB
costimulated CAR (BBz CAR T cells) accumulated over 14 days to yield approximately
1-log more T cells than CD28-costimulated CAR T cells (28z CAR T cells) (Figure
2.1C). This increased expansion is associated with improved viability, which we
observed by a 14% (+/- 3.2%) absolute reduction in T cells that acquired 7AAD
fluorescence and lost mCherry expression on Day 14 for BBz CAR T cells relative to 28z
CAR T cells (Figure 2.1D). To determine if there was also a difference in relative
proliferation, we measured expression of proliferating cell nuclear antigen (PCNA) by
immunoblot (Figure 2.1E) and found no significant difference in PCNA expression
between 28z and BBz CAR T cells at day 0, 7 or 14 following CAR restimulation
(Figure 2.1F).
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Figure 2.1: Irradiated target cell-mediated 4-1BB-costimulated CAR activation
drives greater ex vivo T cell expansion and survival than CD28-costimulated
CAR activation. (A) Representative flow plot of anti-CD19 28z and BBz CAR
expression. (B) Representative ex vivo expansion of CAR T cells stimulated by
irradiated Nalm6 target cells at indicated time points (2:1 T cell to target cell ratio).
(C) Quantification of T cell expansion after 14 days of ex vivo culture represented in
A. (D) Quantification of cell death by % 7AAD+ mCherry- of all events collected on
day 14 of ex vivo culture represented in A. (E) Representative immunoblot of
proliferating cell nuclear antigen (PCNA) at 0, 7, and 14 days of ex vivo culture with
Nalm6 target cells. (F) Immunoblot analysis of PCNA expression on day 14 of ex
vivo culture with Nalm6 target cells. B, C, E n=3 donors from 2 independent
experiments, paired student’s t test.

To identify signaling pathways that drive enhanced BBz CAR T cell survival, we
employed a bead-based artificial antigen presenting cell (APC) approach for activating
CD19-specific CAR T cells. We used magnetic microbeads coated with anti-CD19
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idiotype antibodies to crosslink the anti-CD19 CAR. This approach avoids the
introduction of target cell proteins and RNA that confound analyses of signaling and does
not add additional signals to the CAR T cells through other costimulatory interactions
such as integrin and CD28 activation (Li et al., 2013). Furthermore, such beads have been
used by our group and others to study CAR signaling and its impact on T cell expansion,
metabolism and differentiation (Kawalekar et al., 2016; Ramello et al., 2019; Salter et al.,
2018). Similar to the studies using activation by Nalm6 leukemic cells, BBz CAR T cells
activated by aAPCs also expand about a log more than 28z CAR T cells (Figures 2.2AC). These expansions were less than those achieved with the irradiated target cells, likely
due to a loss of additional costimulatory signals provided by those cells. Even so, we
observed a 8.9% (+/- 3.1%) absolute reduction in 7AAD+, mCherry- cells on Day 14 of
BBz CAR T cells relative to 28z CAR T cells (Figure 2.2D) and did not detect a
significant difference in PCNA expression (Figure 2.2E). From these data, we conclude
that our bead-based expansion system achieves similar outcomes as the irradiated cell
system.
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Figure 2.2: Antigen-coated bead ex vivo expansion system recapitulates relative
expansion, survival, and proliferative differences between 4-1BB- and CD28costimulated CAR T cells. (A) Representative flow plot of anti-CD19 28z and BBz
CAR expression. (B) Representative ex vivo expansion of CAR T cells stimulated by
anti-CD19 idiotype-coated target beads (1:3 T cell to bead ratio) added at day 0 (green
arrow) and removed at day 14 of culture (black arrow). (C) Quantification of T cell
expansion after 14 days of ex vivo culture represented in B. (D) Quantification of cell
death by % 7AAD+ mCherry- of all events collected on day 14 of ex vivo culture
represented in B. C, D n=3 donors from 3 independent experiments, paired student’s t
test. (E) Quantification of western blot analysis of proliferating cell nuclear antigen
(PCNA) at the beginning of, 7, and 14 days of ex vivo culture with target beads (n=3
donors from 3 independent experiments, paired student’s t test).

CAR intracellular domains activate overlapping, but kinetically and quantitatively
distinct signaling pathways upon antigen stimulation
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Both proximal and distal signaling pathways activated by the endogenous TCR
and costimulatory molecules have been reported to influence the proliferation and
survival of T cells following CAR activation (D'Souza et al., 2008; Liu et al., 2016;
Salojin et al., 1999). To determine the kinetics of BBz CAR signaling in our bead-based
system, we assessed p65, and ERK1/2 phosphorylation in BBz CAR T cells at the
indicated intervals over 48 hours (Figure 2.3A). We observed an initial change from
baseline in both pathways within 30 minutes of BBz CAR activation, with ERK1/2
phosphorylation having the largest increase from baseline (Figures 2.3B-D). ERK1/2
phosphorylation did not change further until 12-24 hours following CAR activation,
likely reflecting the activity of CAR-activation induced cytokine production and
signaling (Figure 2.3C-D).
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Figure 2.3: Anti-CD19 BBz CAR activation induces T cell signaling. (A)
Representative immunoblot of p65 and ERK1/2 phosphorylation at the indicated time
points after stimulator bead addition to BBz CAR T cells. (B) Quantification of p65
phosphorylation represented by the immunoblot in A. (C) Quantification of ERK1
phosphorylation represented by the immunoblot in A. (D) Quantification of ERK2
phosphorylation represented by the immunoblot in A. A-D n=3 independent
experiments with 3 donors.

To validate that our bead-based activation system drives similar relative kinetics
in these T cell signaling pathways as has recently been reported (Salter et al., 2018), we
compared Zap-70, p65, and ERK1/2 phosphorylation in T cells expressing an anti-CD19
CAR containing no signaling domains (Dz), the CD3 zeta chain alone (z), also known as
a first-generation CAR, or one of two second-generation combinations, 28z, or BBz
(Figures 2.4 and 2.5). Similar to recent work by Salter et al., 28z CAR mediated Zap70
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phosphorylation was 4.5-fold higher than that mediated by BBz CAR 12 hours after bead
addition and 3.7-fold higher than that mediated by z CAR 30 minutes after bead addition
(Figure 2.5B). p65 phosphorylation at Serine 536, a measure of canonical NF-kB
signaling, increased across all signaling CARs after bead addition, with a trend toward
increased p65 phosphorylation early after activation of the 28z CAR and a small, but
significant increase of 1.34-fold in the BBz CAR relative to that in the 28z CAR at 12 hrs
(Figure 2.5C). Also like the recent work by Salter et al., ERK1 and 2 phosphorylation
both increased with activation of all signaling CARs over time (Figures 2.5D-E) with
ERK2 phosphorylation increased 2.2- and 1.9-fold by 28z and BBz CAR activation,
respectively, relative to that by z-only CAR activation at 30 minutes (Figure 2.5E). We
conclude from these data that the bead-based APC system activates anti-CD19 CARs
leading to CAR signaling in a similar manner to that reported in the literature (Kawalekar
et al., 2016; Salter et al., 2018), providing a robust system for evaluating signaling
downstream of our CD19-specific CARs.
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Figure 2.4: Anti-CD19 CARs and donor CAR expression. (A) Modular
representations of anti-CD19 CARs used, as in Milone, MC et al., 2009. (B)
Expression of each CAR in 3 the donors used. The third donor used a non-transduced
control instead of the non-signaling Dz CAR (Black). z CAR in green, 28z CAR in
red, BBz CAR in blue.
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Figure 2.5 (Previous Page): Anti-CD19 idiotype target beads activate T cell
signaling in anti-CD19 CAR-expressing T cells. (A) Representative western blot of
Zap-70, p65, and ERK1/2 phosphorylation prior to, 30 minutes, and 12 hours after
bead addition to T cells (5:1 bead-to-T cell ratio) expressing anti-CD19 CARs with no
signaling domain (Dz), the CD3z chain intracellular domain only (z), CD28 and CD3z
chain intracellular domains (28z), or 4-1BB and CD3z chain intracellular domains
(BBz). Quantification of western blot analysis of Zap-70 (B), p65 (C), ERK1 (D), and
ERK2 (E) phosphorylation shown in A (green=z, red=28z, and blue=BBz;
quantifications of band fluorescence normalized to loading control, p-values reported
from two-way ANOVA with Tukey’s multiple comparisons test from 3 donors from 3
independent experiments.

4-1BB, but not CD28, co-stimulation potentiates CAR-mediated non-canonical NF-kB
signaling
We hypothesized that the 4-1BB intracellular domain incorporated into a CAR
specifically promotes CAR T cell survival and persistence through activation of ncNF-kB
signaling. In order to interrogate this pathway and establish optimal time points for
comparison across CAR constructs, we first determined the kinetics of activation
following engagement of the BBz CAR (Figure 2.6A). Expression of the initiator kinase
for this pathway, NIK, increased significantly following BBz CAR activation with a peak
of 8.7-fold over baseline also at 12 hours after CAR activation. (Figure 2.6B). We
measured downstream ncNF-kB signaling using the commonly reported metrics of p100
processing: p100 phosphorylation (Figure 2.6C) and p52/p100 ratio (Figure 2.6D)
(Remouchamps and Dejardin, 2015). p100 phosphorylation increased significantly
following bead addition, peaking at 6.1-fold over baseline at 12 hours (Figure 2.6C).
Similarly, the p52/p100 ratio increased significantly over the first twelve hours following
BBz CAR activation, with a peak of 1.87 fold over baseline at 12 hours (Figure 2.6D).
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NcNF-kB signaling culminates in nuclear translocation of RelB and p52. Therefore, we
also measured RelB and p52 nuclear translocation in isolated nuclear fractions, as
confirmed by loss of vinculin (Figure 2.7), at similar time points following BBz CAR
activation using the same initial setup as our assessment of NIK and p100 signal
transduction. Cytoplasmic RelB increased and stayed above baseline after 8 hours of
bead stimulation (Figure 2.7), reflecting previously described increases in expression
following canonical NF-kB signaling (Sanchez-Paulete et al., 2016). Critically, both
RelB and p52 nuclear localization were detectable prior to and increased after BBz CAR
activation (Figure 2.7) indicating tonic signaling and further antigen-mediated activation
of the ncNF-kB pathway. Consistent with the delayed kinetics of this pathway relative to
that of the canonical NF-kB pathway (McPherson et al., 2012), we observed peak ncNFkB signaling 12 hours after anti-CD19 BBz CAR activation.
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Figure 2.6: 4-1BB-costimulated anti-CD19 CAR activation induces non-canonical
NF-kB signaling. (A) Representative immunoblots of NIK stabilization and p100
processing at the indicated times before and after target bead addition to anti-CD19
BBz CAR T cells. (B) Quantitative analysis of immunoblot represented in A of NIK
stabilization (p=0.011). Quantitative analyses of immunoblots represented in A of
p100 phosphorylation (C, p=0.0397), and p100 processing to p52 (D, p52/p100 ratio,
p=0.0244). All p-values generated from 2 independent experiments using CAR T cells
derived from 3 healthy donors by one-way ANOVA from 0.5 to 12-hour time points
of Log2 (Fold Change relative to signal prior to bead addition).
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Figure 2.7: 4-1BB-costimulated anti-CD19 CAR activation RelB/p52 nuclear
translocation. Representative immunoblot of cytoplasmic and nuclear fractions prior
to and at the indicated times after target bead addition to anti-CD19 BBz CAR T cells.
Vinculin used as marker of cytoplasmic fraction and Tata-binding protein (TBP) used
as nuclear loading control (representative of 2 separate experiments using CAR T cells
generated from 2 healthy donors).

To test the hypothesis that ncNF-kB signaling is uniquely activated by 4-1BB costimulated CARs, we compared ncNF-kB signaling by anti-CD19 targeted Dz, z, 28z, or
BBz CARs prior to activation, at 30 minutes, and at 12 hours after bead addition (Figure
2.8A). NIK stabilization trended higher following BBz CAR activation relative to the
other CARs (Figure 2.8B), but this trend was not statistically significant. p100
phosphorylation was 3.2-fold higher 12 hours after bead addition to BBz CAR T cells
relative to 28z CAR T cells (Figure 2.8C). We observed a similar trend in p100
phosphorylation comparing the BBz and z-only CARs. The p52/p100 ratio was increased
in BBz CAR T cells relative to 28z CAR T cells across all time points including prior to
activation (range 1.8- to 2.4- fold higher), whereas no difference in the p52/p100 ratio
was observed between the 28z and z-only CARs (Figure 2.8D). The downstream basal
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ncNF-kB signaling in BBz CAR T cells relative to 28z CAR T cells was also reflected in
increased baseline RelB nuclear occupancy (Figure 2.9A), which was 1.3-fold higher in
BBz CAR T cells relative to 28z CAR T cells (Figure 2.9B). RelB nuclear translocation
increased further 12 hours after CAR activation and was 5.4-fold higher in BBz CAR T
cells relative to 28z CAR T cells (Figure 2.9B). Though we observed increased p52
nuclear occupancy in BBz CAR T cells across all time points relative to z or 28z (Figure
2.9A), this increase reached statistical significance for BBz vs. 28z only at the 30 minute
time point and for BBz vs z only at the 12 hour time point (Figure 2.9C).
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Figure 2.8: Anti-CD19 4-1BB, but not CD28, CAR costimulation drives basal and
enhances CAR activation-induced non-canonical NF-kB signaling. (A)
Representative immunoblots of NIK stabilization and p100 processing at the indicated
times before and after target bead addition to T cells (5:1 bead-to-T cell ratio)
expressing anti-CD19 CARs with no signaling domain (Dz), the CD3z chain
intracellular domain only (z - green), CD28 and CD3z chain intracellular domains
(28z - red), or 4-1BB and CD3z chain intracellular domains (BBz - blue). (B)
Quantitative analysis of immunoblot represented in A of NIK stabilization.
Quantitative analyses of immunoblot represented in A of p100 phosphorylation (C),
and p100 processing to p52 (D). (n=3 donors in 3 independent experiments for all
Log2(Fold Change relative to non-signaling group) quantifications of band
fluorescence normalized to loading control, p-values reported from two-way ANOVA
with Tukey’s multiple comparisons test).
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Figure 2.9: Anti-CD19 4-1BB, but not CD28, CAR costimulation drives basal and
enhances CAR activation-induced RelB/p52 nuclear translocation. (A)
Representative immunoblot of RelB, p52, and TBP in nuclear fractions prior to and at
the indicated times after target bead addition to anti-CD19 CAR T cells as in A.
Quantitative analyses of immunoblots represented in A of nuclear RelB (B), and
nuclear p52 (C). (n=3 donors in 3 independent experiments for all Log2(Fold Change
relative to non-signaling group) quantifications of band fluorescence normalized to
loading control, p-values reported from two-way ANOVA with Tukey’s multiple
comparisons test).

To confirm the unique association between the BBz CAR and ncNF-kB signaling
in a CAR with an alternative scFv and antigen specificity, we compared the p52/p100
ratio in SS1-28z or SS1-BBz CARs targeting mesothelin (Figures 2.10A-B) prior to
activation, at 30 minutes, and at 12 hours after mesothelin-coated bead addition (Figure
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2.10C). Similar to CD19-specific BBz CAR, we observed a higher p52/p100 ratio in the
SS1-BBz CAR compared to SS1-28z CAR in two separate donors prior to activation
(Figures 2.10C-D). Unlike the CD19 CAR, the p52/p100 ratio decreases following
mesothelin-coated bead addition in the SS1-BBz CAR T cells, but it remains higher than
the SS1-28z CAR T cells under the same conditions.
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Figure 2.10: Anti-mesothelin BBz CAR also drives non-canonical NF-kB
signaling. (A) Modular representations of the anti-mesothelin CARs used. (B) 28z
(red) and BBz (blue) CAR expression of live cells from two donors by flow
cytometry. (C) p100 processing to p52 prior to, and following mesothelin-coated bead
addition to CAR T cells from two donors at times indicated. (D) p100 processing to
p52 prior to, and following mesothelin-coated bead addition to CAR T cells from two
donors 2 at times indicated.

In aggregate, these data demonstrate that the BBz signaling domain within the
CAR basally activates the ncNF-kB pathway. Although the degree of antigen-induced
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enhancement of ncNF-kB signaling by BBz CARs differs between the scFv and/or nature
of the ligand, BBz CARs exhibit greater ncNF-kB signaling compared to 28z CARs.
Expression of a dominant-negative NF-kB-inducing-kinase mutant reduces BBzmediated non-canonical NF-kB signaling, ex vivo BBz CAR T cell expansion, and
survival
Targeting NIK has been a widely used strategy to block non-canonical NF-kB
signaling (Sun, 2012). Therefore, we employed this approach to interrupt ncNF-kB
signaling downstream of BBz CAR activation by overexpressing the c-terminus of NIK
(dnNIK) in CAR T cells. DnNIK acts as a dominant-negative mutant by binding p100
and thereby preventing downstream ncNF-kB signaling (Xiao et al., 2001). We
transduced BBz CAR T cells 24 hours after initially transducing the primary human T
cells with the BBz CAR with either a control vector expressing only mCherry, or a
bicistronic vector expressing dnNIK and mCherry (Figure 2.11). This strategy allowed us
to compare ncNF-kB signaling in each group by immunoblotting while maintaining equal
CAR expression across groups (Figure 2.12). We observed a 1.5-fold decrease in
p52/p100 ratio 12 hours after CAR activation in dnNIK expressing T cells relative to
control (Figures 2.13A-B). Similarly, we observed 1.4- and 1.9-fold decreases in RelB
nuclear occupancy 30 minutes and 12 hours, respectively, after BBz CAR activation in
dnNIK expressing T cells relative to control (Figures 2.13C-D). We observed a similar
trend in p52 nuclear occupancy, with significant decreases of 1.9- and 2-fold at baseline
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and 12 hours post CAR activation, respectively, in dnNIK expressing T cells relative to
control (Figures 2.13C, E).
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Figure 2.11: Dual transduced T cell production scheme. Dual transduction
schematic for dominant-negative NIK (dnNIK) CAR T cells.

Having observed a reduction in non-canonical NF-kB signaling by dnNIK
expression, we used this approach in the bead-based CAR T cell expansion model to test
the hypothesis that ncNF-kB signaling is a mediator of anti-CD19 4-1BB co-stimulated
CAR T cell survival.
We observed that dnNIK-expressing BBz CAR T cells expanded 3.1-fold less
than control BBz CAR T cells 14 days after anti-CD19 idiotype bead addition (Figures
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2.14A-B). This reduction in expansion was associated with a 6.2% absolute increase in
cell death assessed by 7AAD uptake by flow on day 14 (Figure 2.14C). We did not detect
a significant difference in PCNA expression between control and dnNIK-expressing BBz
CAR T cells prior to or 14 days after CAR T cell activation (Figure 2.14D). To exclude
that dnNIK expression was non-specifically causing CAR T cell death following CAR
activation, we conducted these studies in anti-CD19 28z CAR T cells in parallel (Figure
2.15). We observed no significant differences in expansion (Figures 2.15A-B), 7AAD
uptake (Figure 2.15C), or PCNA expression (Figure 2.15D) between control and dnNIKexpressing 28z CAR T cells on day 14 of culture. These data demonstrate that 4-1BBcostimulated anti-CD19 CAR T cells specifically require ncNF-kB signaling to promote
cell survival.
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Figure 2.13 (Previous Page): Dominant-negative NIK expression reduces noncanonical NF-kB signaling. (A) Representative immunoblot of p100 processing to
p52 at indicated times after target bead addition to anti-CD19 BBz CAR T cells
expressing either mCherry (control) or dnNIK. (B) Quantitative analysis of p52/p100
ratio from immunoblots represented in A. (Quantification in A performed on p52/p100
ratio. Analysis in B performed on Log2 of fluorescence of p52/p100 ratio of 3
independent experiments of CAR T cells generated from 3 donors. P-values reported
from 2-way ANOVA with Holm-Sidak’s multiple comparisons test.) (C)
Representative immunoblot of RelB, p52, and TBP in nuclear fractions of anti-CD19
BBz CAR T cells as in A. Quantitative analyses of nuclear localization of RelB (D)
and p52 (E) from immunoblots represented in C. (Quantification in C performed on
RelB or p52 normalized to TBP loading control. Analysis in D and E performed on
Log2 of fluorescence of protein of interest normalized to the fluorescence of TBP from
2 independent experiments of CAR T cells generated from 3 donors. P-values reported
from 2-way ANOVA with Holm-Sidak’s multiple comparisons test.)
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Figure 2.14: Dominant-negative NIK-mediated non-canonical NF-kB suppression
diminishes BBz CAR T cell ex vivo expansion and survival. (A) Representative ex
vivo expansion of control or dnNIK BBz CAR T cells stimulated by anti-CD19
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7AAD+ mCherry- of all events collected (C) and PCNA expression (D) on day 14 of
ex vivo culture represented in A. All p-values derived from paired student’s t-tests
from 4 donors in 4 independent experiments.
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Figure 2.15: Dominant-negative NIK-mediated non-canonical NF-kB suppression
has no effect on 28z CAR T cell ex vivo expansion and survival. (A)
Representative ex vivo expansion of control or dnNIK 28z CAR T cells stimulated by
anti-CD19 idiotype-coated target beads (1:3 T cell to bead ratio) added at day 0 (green
arrow) and removed at day 14 of culture (black arrow). (B) Quantification of T cell
expansion after 14 days of ex vivo culture represented in A. Quantification of cell
death by % 7AAD+ mCherry- of all events collected (C) and PCNA expression (D)
on day 14 of ex vivo culture represented in A. All p-values derived from paired
student’s t-tests from 4 donors in 4 independent experiments.

Oxidative metabolism is unaffected by non-canonical NF-kB blockade
Cell-intrinsic and TNFRSF-mediated ncNF-kB signaling in skeletal muscle fibers
and osteoclasts, respectively, drives oxidative metabolism (Bakkar et al., 2012; Zeng et
al., 2015). Oxidative metabolism supports memory T cell survival (van der Windt et al.,
2012), and central memory T cells are enriched by anti-CD19 BBz CAR activation
(Kawalekar et al., 2016). We determined that BBz CARs activate ncNF-kB signaling,
which supports anti-CD19 BBz CAR T cell survival. From these observations, we
hypothesized that the reduced survival of dnNIK-expressing BBz CAR T cells is due at
least in part to a loss in oxidative metabolism. To test this hypothesis, we measured the
oxygen consumption and extracellular acidification rates of control or dnNIK-expressing
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anti-CD19 BBz CAR T cells before and 14 days after anti-CD19 idiotype bead-based
bead activation (Figure 2.16). We observed no differences in basal or maximal oxygen
consumption rate (Figure 2.16A) or extracellular acidification rate (Figure 2.16B)
between control and dnNIK-expressing cells at either time point. We did observe that day
14 cells have a higher basal and maximal ECAR than their unstimulated counterparts
(Figure 2.16B). This increased ECAR reflects that the T cells have been activated, as is
consistent with previous reports (MacIver et al., 2013). From these data, we conclude that
ncNF-kB signaling is not responsible for supporting oxidative metabolism in anti-CD19
BBz CAR T cells.
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Figure 2.16: Dominant-negative NIK expression does not impact BBz CAR T cell
oxygen consumption or glycolysis. (A) Control (blue) and dnNIK (red) anti-CD19
BBz CAR T cell oxygen consumption rate prior to and 14 days after bead expansion.
First three data points represent basal oxygen consumption and third set of data points
represent maximal oxygen consumption induced by FCCP. (B) Extracellular
acidification rate of these cells on days indicated. First three data points represent
basal glycolytic rate. Second set of three represent maximal glycolytic rate induced by
oligomycin.

4-1BB costimulation-mediated non-canonical NF-kB signaling represses pro-apoptotic
protein, Bim
NcNF-kB signaling in multiple myeloma cell lines and 4-1BB costimulation in T
cells have both been shown to enhance cell survival by suppressing expression of the proapoptotic protein Bim (Sabbagh et al., 2008; Vallabhapurapu et al., 2015; Wang et al.,
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2008). From our observation that ncNF-kB signaling supported BBz CAR T cell
survival, we hypothesized that the increased cell death observed with reduced ncNF-kB
signaling in BBz CAR T cells is due at least in part to increased Bim expression. To
evaluate this, we assessed Bim expression by immunoblot at baseline and 14 days after
anti-CD19 idiotype bead addition in CD19-specific BBz (Figure 2.17) and 28z (Figure
2.18) CAR T cells transduced with a dnNIK or a control vector. No significant difference
was detected in any of the Bim isoforms at baseline between dnNIK or control transduced
BBz (Figure 2.17B-D) or 28z (Figure 2.18B-D) CAR T cells. BimL expression was
significantly higher in BBz cells transduced with the dnNIK vector when compared to the
control vector at day 14 (Figure 2.17F) with a similar trend observed for BimS (Figure
2.17G). No difference in any of the isoforms of Bim was apparent in 28z CAR T cells at
day 14 (Figure 2.18E-G).
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Figure 2.17: 4-1BB-costimulation-mediated non-canonical NF-kB signaling
opposes expression of pro-apoptotic protein, Bim. (A) Representative western blot
of Bim isoform expression prior to and 14 days after ex vivo bead expansion in control
or dnNIK BBz CAR T cells. Quantitation of western blot of baseline BimEL (B), BimL
(C), and BimS (D) expression, and expression of BimEL (E), BimL (F), and BimS (G)
14 days after bead addition as represented in A. B-G All p-values derived from paired
student’s t-tests from 4 donors in 4 independent experiments.
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Comparing Bim isoform expression between 28z and BBz CAR T cells at baseline
(Figure 2.19) demonstrated a significant decrease in BimS in BBz cells (Figure 2.19C)
with a similar trend in BimL (Figure 2.19B). Together, the differential Bim isoform
expression observed prior to CAR activation between 28z and BBz CAR T cells with
especially low levels of BimS expression in BBz cells and the increase in Bim isoform
expression in the context of dnNIK following CAR activation are consistent with Bim as
a target of ncNF-kB signaling in BBz CAR T cells. The failure to detect a difference in
Bim isoform expression when ncNF-kB signaling is disrupted by dnNIK prior to CAR
activation may be a result of the low overall expression of the BimS and BimL.
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Figure 2.19: In the absence of antigen, anti-CD19 BBz CAR T cells express less of
the two most potent isoforms of Bim than 28z CAR T cells. Quantitation of western
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Though previous work in multiple myeloma cell lines has demonstrated
cooperative suppression of Bim by ERK and non-canonical NF-kB signaling
(Vallabhapurapu et al., 2015), prior studies in T cells have only addressed ERK-mediated
Bim suppression (Luciano et al., 2003; O'Reilly et al., 2009; Sabbagh et al., 2008).
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Figure 2.20: Control vs. dnNIK BBζ CAR T cell ERK1/2 Phosphorylation. (A)
Representative immunoblot of ERK1/2 phosphorylation at the indicated time points
after stimulator bead addition to BBz CAR T cells expressing mCherry (control) or
dominant-negative NIK (dnNIK). (B) Quantification of ERK1 phosphorylation
represented by the immunoblot in A. (C) Quantification of ERK2 phosphorylation
represented by the immunoblot in A. P-value from 2-way ANOVA with Holm-Sidak’s
multiple comparisons test of 3 independent experiments from 3 donors.

Therefore, we assessed ERK phosphorylation in the dnNIK-expressing BBz CAR T cells
to determine if dnNIK expression impacted BBz CAR-mediated ERK activation (Figure
2.20A). Thirty minutes after bead addition, we observed a 1.2-fold reduction in ERK1
phosphorylation in dnNIK-expressing CAR T cells relative to controls, but no significant
difference in ERK1 phosphorylation prior to or 12 hours after bead addition (Figure
2.20B). We also observed no significant difference in ERK2 phosphorylation at any time
63

point (Figure 2.20C). Thus, although the reduction in ERK1 phosphorylation upon
activation in dnNIK-expressing CAR T cells is small and transient, we cannot completely
rule out that the observed reductions in Bim expression are not in part due to small
reductions in ERK signaling.
Another transcription factor known to drive Bim expression in T cells is FOXO3a
(Riou et al., 2007). FOXO3a is regulated by numerous signaling pathways, including by
g-chain cytokines through phosphorylation of threonine 32 and subsequent proteosomal
degradation (Riou et al., 2007; Sunters et al., 2003). To determine if g-chain cytokine
signaling is affected by dnNIK expression and impacts Bim expression through FOXO3a
regulation, we assessed FOXO3a phosphorylation at threonine 32 and total FOXO3a
expression in the control and dnNIK-expressing BBz CAR T cells at Day 0 and Day 14
of expansion (Figure 2.21). We observed no significant differences in FOXO3a
expression between the control and dnNIK-expressing groups at either timepoint (Figure
2.21B), instead observing a loss of FOXO3a expression from D0 to D14. We were also
unable to detect any phosphorylation of FOXO3a at threonine 32 in any of the samples
(Figure 2.21A). Instead, we detected phosphorylation of FOXO1 at threonine 34, which
can be distinguished by its smaller size relative to FOXO3a (Figure 2.21A). From these
data, we conclude that FOXO3a is not being modulated by dnNIK expression and is
unlikely to contribute to changes in Bim expression.
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DISCUSSION
We have shown that the 4-1BB cytoplasmic domain incorporated into a CAR
potently activates non-canonical NF-kB signaling in human T cells. This activation
appears constitutive across two 4-1BB-costimulated CARs with independent antigenic
specificity, and it is also increased in CD19-specific BBz CAR T cells upon CAR
engagement with ligand when compared with a 1st generation CAR or a CD28costimulated CAR. Moreover, disruption of this pathway significantly impairs anti-CD19
CAR T cell survival following BBz CAR-mediated activation leading to reduced T cell
expansion ex vivo. The latter is associated with increased expression of the pro-apoptotic
protein, Bim, shown to mediate the pro-survival effects of ncNF-kB signaling in other
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systems (Vallabhapurapu et al., 2015; Wang et al., 2008). Our study is the first to our
knowledge to demonstrate that the 4-1BB costimulatory domain within a CAR directly
promotes T cell survival via the non-canonical NF-kB pathway, consistent with previous
reports demonstrating that murine endogenous 4-1BB costimulation activates the ncNFkB signaling (McPherson et al., 2012), whereas endogenous CD28 costimulation does
not (Li et al., 2005; Marinari et al., 2004). It also adds to our understanding of CAR
costimulation as prior published reports have implicated faster and more potent proximal
signaling by CD28-costimulated CARs to explain the differences between 4-1BB and
CD28 costimulated CAR T cell survival (Salter et al., 2018) whereas our results provide
an additional mechanism directed by the 4-1BB domain itself.
A frequently observed feature of 4-1BB co-stimulated CARs is basal signaling in
the absence of antigen, so called “tonic” signaling (Ajina and Maher, 2018; Frigault et al.,
2015; Milone et al., 2009). Our data is consistent with these previous reports, and we also
observe CD28-costimulated CAR basal signaling through the Zap70 pathway (Figures
2.5A-B, (Salter et al., 2018)). 4-1BB-costimulated CAR basal signaling appears to occur
through both the canonical (Figure 2.5A, C, (Li et al., 2018)) and non-canonical (Figures
2.6-10) NF-kB pathways, with the latter detectable by increased baseline p100 processing
(Figure 2.8D and 2.10D) and RelB nuclear localization (Figure 2.9B). This basal ncNFkB signaling is consistent across anti-CD19 and anti-mesothelin CARs. Intriguingly, not
all pathways downstream of CAR activation are basally active. ERK phosphorylation is
undetectable prior to CAR activation (Figures 2.5A, D-E), and ERK2 phosphorylation,
specifically at 30 minutes post CAR activation, was a statistically significant marker of
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costimulation (Figure 2.5E). These distinct signaling modalities of CARs may arise from
the constitutive dimerization of the CAR caused by disulfide bridges between the CD8
hinge domains or associations between neighboring scFv’s (Harris and Kranz, 2015;
Snow and Terhorst, 1983). Though the native 4-1BB can form dimers linked by disulfide
bonds (Bitra et al., 2018), trimerization by its ligand, 4-1BBL, initiates downstream
signaling (Bitra et al., 2018; Gilbreth et al., 2018b; Won et al., 2010; Zapata et al., 2018;
Zheng et al., 2010). Whereas CD28-costimulated CAR basal signaling has been
consistently shown to be detrimental to CAR T cell function and persistence (Long et al.,
2015; Zheng et al., 2018), basal ncNF-kB signaling enhances cell survival of multiple
cell types, including T cells (Wang et al., 2008; Wharry et al., 2009). These observations
are consistent with the BBz CAR-associated enhanced survival of both anti-CD19
(Milone et al., 2009; Mueller et al., 2018) and anti-mesothelin (Wang et al., 2015) CAR T
cells. NcNF-kB signaling integrates with ERK and other signaling pathways to achieve
these effects (House et al., 2018; Li et al., 2015; Liu et al., 2019; Shinzawa et al., 2015;
Vallabhapurapu et al., 2015), emphasizing the importance of further understanding how
CARs activate some pathways in the absence of antigen and others only upon
crosslinking, and how these signals combine to impact T cell function.
Whereas the basal activation of ncNF-kB signaling was consistent across two
CARs with different scFv and antigen specificity, the observed difference in ligandinduced enhancement of the pathway between the CD19-specific and mesothelin-specific
CAR was unexpected. We have previously reported on the higher tonic signaling of the
mesothelin-specific BBz CAR incorporating the SS1 scFv (Frigault et al., 2015).
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Although speculative, this increased tonic signaling may lead to higher basal ncNF-kB
signaling that is closer to the maximal response thereby blunting our ability to see a
different upon activation. In this case, the small reduction that we observed in the
p52/p100 ratio following bead activation could be due to increased p100 expression due
to increased canonical NF-kB signaling (Li et al., 2018; Mukherjee et al., 2017).
Alternatively, differences in the way that the CAR engages antigen or in the way that the
antigen is presented for these two scFv-ligand systems might also influence liganddependent activation of the ncNF-kB pathway downstream of a BBz CAR. In particular,
CARs, like TCR/CD3 complex, internalize following antigen engagement, and the degree
of internalization has been associated with ligand density as well as receptor affinity,
which are not controlled in our activation system (Liu et al., 2000; Walker et al., 2017).
This internalization can negatively impact CAR function (Walker et al., 2017) and could
lead to diminished ncNF-kB signaling.
It is likely that the signaling downstream of 4-1BB costimulation that we
observed will extend to other TNFRSFs that also activate the non-canonical NF-kB
pathway. Transient expression of OX40L on both activated CD4 and CD8 T cells (Kondo
et al., 2007; Soroosh et al., 2006) can activate OX40 and downstream ncNF-kB signaling
(Murray et al., 2011). This OX40-OX40L interaction may explain the small increase in
ncNF-kB signaling we observed in the z-chain and 28z CARs (Figure 4) as both OX-40
and OX-40L are inducted upon T cell activation (Soroosh et al., 2006). Other groups
have incorporated OX40 co-stimulation directly into the CAR, thereby achieving
enhancements in function and persistence (Hombach and Abken, 2011), likely, at least in
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part, by activation of ncNF-kB signaling. Similar results may be achieved by using the
intracellular domains of a number of TNFRSFs that bind TRAF2 and TRAF3 (Sun,
2017). However, not all TNFRSFs activate non-canonical NF-kB signaling. For example,
TNFR1 cannot activate ncNF-kB signaling (Festjens et al., 2007; Kim et al., 2011).
Conversely, BAFFR activates ncNF-kB, but not canonical NF-kB signaling (Stadanlick
et al., 2008). NcNF-kB signaling in the absence of canonical NF-kB signaling results in
loss of p100 and attenuation of ncNF-kB signaling (Stadanlick et al., 2008), suggesting
that domains from TNFRSFs, such as 4-1BB, are most likely to drive CAR T cell
persistence through a combination of canonical and non-canonical NF-kB signaling.
Approaches to pharmacologically activate the ncNF-kB pathway may also have
utility, especially in T cell-based immunotherapies that do not utilize TNFRSF-based
costimulation. One class of molecules, SMAC mimetics, have already been leveraged in
combination with CAR T cells to enhance target-negative tumor cell killing (Michie et
al., 2019). SMAC mimetics activate ncNF-kB signaling (Tchoghandjian et al., 2013) and
enhance T cell expansion and function (Dougan et al., 2010). Based on our observations
that 4-1BB co-stimulation-mediated ncNF-kB signaling is a driver of anti-CD19 CAR T
cell survival, it may be possible to use SMAC mimetics to similarly enhance nonTNFRSF costimulated T cells. This combination may be especially beneficial in
transgenic T cell receptor directed T cell therapies, which have no synthetic costimulation
(Krummel et al., 1999). The tumor responses induced by theses therapies correlate with
persistence (Johnson et al., 2009), which, based on our findings and previous reports of
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SMAC mimetic effects on T cells (Beug et al., 2017; Dougan et al., 2010), could be
increased by SMAC mimetic-mediated ncNF-kB signaling.
Finally, our study has provided some insight into the mechanism by which ncNFkB signaling by the 4-1BB domain of the CAR promotes T cell survival. We initially
hypothesized that ncNF-kB-driven anti-CD19 BBz CAR T cell survival was supported
by oxidative metabolism. As such, we expected that dnNIK-expressing anti-CD19 BBz
CAR T cells would have lower maximal oxygen consumption and spare respiratory
capacity. We were somewhat surprised that we did not detect any differences in either of
these measurements between control and dnNIK-expressing anti-CD19 BBz CAR T
cells both prior to and 14 days after CAR activation (Figure 2.16A). These data suggest
that BBz CAR-associated oxidative metabolism is driven by other mechanisms. There are
at least three possible mechanisms that could explain this finding. First, it is still possible
that NIK stabilization contributes to mitochondrial respiration, but does so by directly
associating with mitochondria instead of through downstream ncNF-kB signaling (Jung
et al., 2016). DnNIK only interferes with interactions mediated by the c-terminus of NIK,
which may not be responsible for its mitochondrial activity. However, BBz CARassociated oxidative metabolism was associated with increased expression of TFAM, a
regulator of mitochondrial biogenesis. Therefore, we believe it is more likely that other
pathways may be responsible BBz CAR-associated oxidative metabolism. Recently,
endogenous 4-1BB activation was found to drive murine T cell oxidative metabolism by
p38 MAPK-mediated PGC1a expression (Menk et al., 2018). PGC1a binds the TFAM
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promoter thereby inducing its expression (Wu et al., 1999). These findings suggest that
BBz CAR signaling may not simply be associated with oxidative metabolism, but may
drive it directly through p38 MAPK signaling. There is at least one other explanation of
our data that we must address. Both our experiments and those first connecting antiCD19 BBz CAR signaling to oxidative metabolism (Kawalekar et al., 2016) were
performed in the presence of IL-15. IL-15 can independently drive oxidative metabolism
in T cells (Bordon, 2012). Furthermore, T cell metabolism can be driven towards a
glycolytic phenotype by CD28 activation (Frauwirth et al., 2002). Therefore, it is possible
that the reported connection between anti-CD19 BBz CAR signaling and oxidative
metabolism may be due to IL-15, the effect of which may be overcome by 28z CARdriven glycolytic polarization. In any case, we conclude that BBz CAR-driven ncNF-kB
signaling is not responsible for BBz CAR-associated oxidative metabolism, and therefore
supports anti-CD19 BBz CAR T cell survival by another mechanism.
NcNF-kB signaling enhances survival of both myeloma cells and T cells by
suppression of the pro-apoptotic protein, Bim (Vallabhapurapu et al., 2015; Wang et al.,
2008). Bim plays a central role in T cell survival with expression that increases with T
cell activation, and is repressed by ERK signaling (Bouillet et al., 2002; Hildeman et al.,
2002; Masson et al., 2011; Wojciechowski et al., 2006). The latter was previously
identified as a key mechanism by which endogenous murine 4-1BB enhances T cell
survival (Sabbagh et al., 2008); however, ncNF-kB signaling has been implicated with
ERK signaling in Bim regulation within multiple myeloma suggesting that these two
pathways are not mutually exclusive (Vallabhapurapu et al., 2015). In particular, ERK
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influences the cellular abundance of Bim in at least two ways: cooperation with RelB/p52
dimers to inhibit Bim transcription (Vallabhapurapu et al., 2015), and through the
phosphorylation and subsequent degradation of the BimEL isoform (Ley et al., 2005;
Luciano et al., 2003). This latter function of ERK may explain why we did not observe
differences in BimEL expression between anti-CD19 28z and BBz CAR T cells or
between dnNIK expressing BBz CAR T cells relative and their controls (Figures 2.17B,
E, 2.19A, D), given that ERK is active in both settings (Figures 2.5D-E, 2.20) (Salter et
al., 2018). The observed increases in BimL and BimS expression in dnNIK expressing
BBz CAR T cells relative to controls after CAR activation (Figures 2.17F-G) are
consistent with a transcriptional effect. In addition, the BimL and BimS isoforms are even
more potent sensitizers to apoptosis than BimEL (O'Connor et al., 1998) and are capable
of diminishing T cell survival in the absence of BimEL (Clybouw et al., 2012). Although
we were unable to detect a difference in BimL and BimS expression between anti-CD19
28z and BBz CAR T cells following CAR-mediated expansion despite baseline
differences, this may be due to selection events occurring in the 28z culture as observed
with the early loss of cells upon bead stimulation (Figure 2.15A) and consistent with
previous work describing rapid 28z CAR T cell effector differentiation and cell loss
(Kawalekar et al., 2016; Salter et al., 2018). Bim suppression is an important downstream effect of 4-1BB-induced ncNF-kB signaling and likely contributes to BBz CARmediated T cell survival, and further studies are needed to identify additional ncNF-kB
responsive genes that may also contribute to this survival.
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Our system has allowed us to identify non-canonical NF-kB signaling as a
specific and critical mediator of 4-1BB co-stimulated CAR T cell survival, but we must
also acknowledge some of its limitations. In this report, we have focused upon anti-CD19
CARs, which our group (Carpenito et al., 2009; Milone et al., 2009), and Salter et. al
(Ramello et al., 2019; Salter et al., 2018) have employed to study CAR signaling. Though
it is possible that our findings regarding CAR T cell survival are limited to the anti-CD19
CAR, 4-1BB-costimulated CAR T cells targeting multiple other antigens have been
described as having similar enhanced survival (Guedan et al., 2018; Priceman et al.,
2018; Song et al., 2011; Wang et al., 2015). The overexpressed, dominant-negative
mutant of NIK was chosen for our studies due to the well described effects of this
approach in disrupting ncNF- B (Xiao et al., 2001), and the lack of commercially
available pharmacological inhibitors (Paul et al., 2018) or efficient gene-editing
technologies to silence expression of an intracellular protein in primary human T cells
(Chen, 2015). Although protein overexpression and dominant negative mutants can have
unintended, off-target effects, the absence of an appreciable impact of dnNIK expression
on both polyclonal T cell expansion via anti-CD3/anti-CD28 beads or 28z CAR-mediated
expansion supports the generally non-toxic and targeted nature of our approach (Figures
2.15A-B).
In summary, we have identified an essential and non-redundant mechanism by
which 4-1BB costimulation within a CAR supports T cell survival: namely by mediating
both basal and ligand-dependent activation of non-canonical NF-kB signaling, which is
associated with reduced expression of the most pro-apoptotic isoforms of Bim. NcNF73

kB signaling by 4-1BB-costimulated CARs also likely influences gene expression in
CAR T cells beyond those affecting survival and persistence, as this pathway regulates
the expression of many genes such as chemokines and cytokines that are important for T
cell trafficking and function (Sun, 2017). Although not evaluated in our study, ncNF-kB
signaling has been reported to be required for GM-CSF production by Th17 cells (Yu et
al., 2014) suggesting that the 4-1BB-induced activation of this pathway could play a role
in cytokine release syndrome that depends upon this cytokine (Sachdeva et al., 2019;
Sterner et al., 2019). Our study therefore represents only a beginning for the study of this
unique and complex signaling pathway in CAR T cells that clearly deserves further
exploration.
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MATERIALS AND METHODS
Primary Cells and Nalm6 cells
Primary human T cells were procured and cultured as described previously
(Milone et al., 2009). Briefly, peripheral blood mononuclear cells were collected from
anonymous healthy donors by aphaeresis. T cells were isolated from these aphaeresis
products by the University of Pennsylvania Human Immunology Core using Lymphoprep
and RosetteSep human T cell Enrichment Cocktail kits (Stem Cell Technologies) per
manufacturer’s instructions. Primary human T cells were cultured at 37°C in RPMI 1640
media (Gibco) supplemented with 10% FBS, HEPES buffer (final concentration 10 mM),
penicillin (100 units/mL) and streptomycin (100 µg/mL). Nalm6 cells (ATCC) were
cultured at 37‡C in the same media as T cells, and re-fed every other day to a
concentration of 0.25e6 cells/mL. Immediately prior to use as stimulator cells, Nalm6
cells were irradiated with 100 Gy using an X-ray irradiator.
Generation of high-titer lentiviral vectors and T cell transduction
All CAR constructs used were constructed as previously described (Fig. S14)
(Carpenito et al., 2009; Milone et al., 2009). All lentiviral vectors were produced and
used to transduce primary human T cells for all single transduced T cell assays as
previously described (Milone et al., 2009). Dual transduced CAR T cells were generated
as follows. We transduced T cells with anti-CD19 CARs containing either CD28 or 41BB costimulatory domains from healthy donor bulk T cells using lentiviral transduction,
as described previously (Milone et al., 2009). These cells were subsequently transduced a
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second time with either a control lentiviral vector expressing mCherry, or a bicistronic
vector expressing a dominant-negative mutant of NF-kB-inducing kinase and mCherry,
which were separated in the vector by a T2A site. These dual transduced cells were
cultured for 5-8 days, sorted to purity on mCherry expression, and further expanded with
IL-7 and IL-15 (Premium grade, Miltenyi Biotec, 10 ng/mL final concentration) added
with R10 media every other day to maintain a starting concentration of .75e6 cells/mL.
This expansion regimen was maintained until the cells plateaued in size as measured on a
Coulter Counter (Beckman Coulter) for two consecutive measurements. These cells were
either immediately used in assays (described as “fresh”) or cryopreserved as described
previously (Milone et al., 2009). Cells were enumerated by combining counts collected
on a Coulter Counted (Beckman Coulter) with viability as assessed by flow cytometry
using 7AAD (Cell viability solution, BD Via-Probe) exclusion (Fig. S15A). CD4
(BUV395, RPA-T4, BD Biosciences), CD8 (BV785, RPA-T8, BioLegend), and CD19
(APC, HIB19, STEMCELL) expression were also assessed by flow cytometry.
Elimination of irradiated Nalm6 stimulator cells by day 3 following addition was
confirmed by the absence of CD19+ cells (Figure 2.22).
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Figure 2.22: Representative gating strategy to quantify cell death by flow
cytometry and assess CD19+ Nalm6 cell elimination. (A) T cell culture gating
strategy shown for D14. 7AAD+ mRFP- events were counted as dead cells. 7AADmRFP- events were assessed for CD19+ expression. (B) All mCherry negative, 7AAD
negative cells stained for CD19 prior to second round of irradiated Nalm6 addition
(Day 7), 3 days later (Day 10), and 5 days later (Day 12). All mCherry negative,
7AAD negative events from Nalm6-only parallel culture assessed on D14 of T cell
culture shown for CD19 positive control.

Preparation and use of stimulation beads
Stimulator beads were prepared as described previously (Kawalekar et al., 2016).
Briefly, Dynabeads M-450 Tosylactivated (Invitrogen) were washed and resuspended in
a pH 9.5 borate buffer at 4e8/mL, incubated overnight with 150 µg of anti-CD19 idiotype
antibody (Novartis) or mesothelin-Fc at 37°C with constant mixing. The beads were then
washed 3 times in a wash buffer (3% human AB serum, 0.1% sodium azide, and 0.4%
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0.5M EDTA in PBS) at 4°C for 10 minutes each with constant mixing, followed by an
overnight wash at 4°C in the same buffer with constant mixing. Prior to use, beads were
washed 3 times in PBS, and then resuspended in the same RPMI-based media as above.
Before use in experiments, beads were QC’d by mixing with BBz CAR T cells at a 3:1
bead-to-cell ratio. Bead activity was assessed by T cell size measured by Coulter Counter
after 3 days compared to the same BBz CAR T cells mixed with previous batches of
beads at the same ratio used in parallel as a positive control, and BBz CAR T cells alone
as a negative control. Beads were then used at a 3:1 bead-to-cell ratio for all bead-based
expansion assays, and at a 5:1 bead-to-cell ratio for all signaling assays. T cells for
expansion assays were mixed with beads and cultured as above. T cells for stimulation
assays were mixed with beads and spun down to synchronize bead-cell contact. They
were then incubated at 37°C for the indicated time periods.
Whole cell lysis
Ripa buffer stock was made at 1X consisting of 150 mM NaCl, 1% NP-40, 0.5%
Deoxycholate, 0.1% SDS, and 50 mM Tris at pH 8.0. The stock was stored at 4°C. The
night before use, one tablet each of phosphatase inhibitor (PhosSTOP, Roche) and
proteasome inhibitor (cOmplete, Roche) was added to a working volume of Ripa buffer.
On the day of lysate collection, T cells were harvested from cell culture, washed with icecold PBS (Corning), and resuspended in the working stock of ice-cold Ripa buffer.
Lysates were incubated on ice for 30 minutes, while being vortexed at maximum for 10
seconds at 10 minute intervals. They were then spun down at 16,000 x g for 10 minutes
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in a refrigerated centrifuge. The supernatants were collected, aliquoted and immediately
frozen at -80°C.
Nuclear/Cytoplasmic fractionation
Our nuclear/cytoplasmic fractionation technique was adapted from a previously
described method (Madge and May, 2009). Cytoplasmic buffer stock was made at 1X
consisting of 10 mM HEPES, 10 mM KCl, and 0.1 mM EDTA, adjusted to pH 7.9.
Nuclear buffer stock was made at 1X consisting of 20 mM HEPES, 0.42 M NaCl, and 0.1
mM EDTA, adjusted to pH 7.9. Both buffers were stored at 4°C. The night before use,
one tablet each of phosphatase inhibitor (PhosSTOP, Roche) and proteasome inhibitor
(cOmplete, Roche) was added to a working volume of each buffer. On the day of lysate
collection, T cells were harvested from cell culture, washed with ice-cold PBS (Corning),
and resuspended in the working stock of ice-cold cytoplasmic buffer. Samples were
incubated on ice for 10 minutes. A final concentration of 0.1% NP-40 (ThermoFisher
Scientific) was added to each sample. Each sample was then incubated at room
temperature for 5 minutes, followed by a 10 second maximum speed vortex, and
immediate centrifugation at 4000 x g for 90 seconds at 4°C. Supernatants were collected
on ice, aliquoted, and frozen at -80°C for later use as the cytoplasmic fraction. The
remaining nuclear pellets were washed twice with ice-cold cytoplasmic buffer, and
transferred to a fresh tube. They were then resuspended in ice-cold nuclear buffer and
shaken at 4°C for 30 minutes at 1400 rpm. Samples were then spun at 16,000 x g for 15
minutes at 4°C. Supernatants were collected, aliquoted on ice, and stored at 80°C to be
used as nuclear fractions.
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Western Blot Analysis
Lysates were thawed on ice, and protein concentration was assessed by DC
Protein Assay (Bio-Rad) as per manufacturer’s instructions. Equal quantities of protein
were added to Laemmli buffer (Bio-Rad) containing 2-mercaptoethanol (Bio-Rad) and
boiled at 95°C for 5 minutes. Protein was separated in NuPAGE gels using the Cell
SureLock Mini-Cell (Invitrogen) and transferred to a methanol-activated PVDF-FL
membrane (Millipore Sigma) in the Mini Trans-Blot Electrophoretic Transfer Cell (BioRad) in 10% methanol NuPAGE transfer buffer (ThermoFisher Scientific). Following
transfer, the membranes were incubated in methanol for 1 minute, followed by a
deionized water wash, then incubated in TBS for 2 minutes, prior to blocking in TBS
Odyssey blocking buffer (LI-COR) for 1 hour. Proteins were visualized using the
following primary antibodies, incubated overnight at 4°C in TBS Odyssey blocking
buffer (LI-COR) with 0.5% Tween 20 (Bio-Rad): PCNA (PC10, 1:2000, Cell Signaling
Technology), Actin (8H10D10, 1:1000, Cell Signaling Technology), Phospho-Zap-70
(Tyr319, 65E4, 1:1000, Cell Signaling Technology), Zap-70 (L1E5, 1:1000, Cell
Signaling

Technology),

Phospho-p65

(Ser536,

93H1,

1:1000,

Cell

Signaling

Technology), p65 (L8F6, 1:1000, Cell Signaling Technology), Phospho-p44/42 MAPK
(ERK1/2) (Tyr202/Tyr204, D13.14.4E, 1:2000, Cell Signaling Technology), p44/42
MAPK (ERK 1/2) (L34F12, 1:2000, Cell Signaling Technology), NIK (1:750, Cell
Signaling Technology), Phospho-NF-kB2 p100 (Ser866/870, 1:1000, Cell Signaling
Technology), Anti-NF-kB p52 (1:1000, Millipore Sigma), RelB (D7D7W, 1:1000, Cell
Signaling Technology), Bim (C34C5, 1:1000, Cell Signaling Technology). Each
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membrane was only incubated with one primary antibody from a single origin species
(Rabbit or Mouse) at one time. The membranes were washed with TBS containing 0.1%
Tween 20, and incubated with Donkey anti-Rabbit (IRDye 800CW, 1:15000, LI-COR)
and/or Donkey anti-Mouse (IRDye 680RD, 1:15000, LI-COR) secondary antibodies in
TBS Odyssey blocking buffer (LI-COR) with 0.5% Tween 20 and 0.1% SDS
(ThermoFisher Scientific) for 40 minutes at room temperature. The membranes were then
washed again with TBS containing 0.1% Tween 20, rinsed once in TBS, and then kept in
TBS at 4°C until imaging. Membranes were imaged using the Odyssey CLx (LI-COR)
and fluorescence was evaluated using Image Studio (LI-COR). When membranes were
re-probed to visualize additional proteins, they were first re-blocked in TBS Odyssey
blocking buffer (LI-COR) for 1 hour at room temperature, and then steps were repeated
as above.
Metabolic phenotype analysis
Mitochondrial respiration and cellular glycolytic rate were assessed using an
XF96 extracellular flux analyzer (Seahorse Bioscience). CAR T cells were metabolically
phenotyped prior to and 14 days after coculture with anti-CD19 idiotype antibody-coated
beads, as described above. Analysis was conducted as described previously (Kawalekar
et al., 2016).
Statistical analysis
Results are expressed as a mean +/- standard deviation. All Log FC values are
derived as follows: Log2 of ((@ time of interest of experimental group: raw fluorescence
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of the protein of interest/raw fluorescence of relevant loading control)/(@ control time
point of control group: raw fluorescence of protein of interest/raw fluorescence of
relevant loading control)). Statistical comparisons were made as listed in figure legends,
with factors of 2-way ANOVA analyses being CAR and Time, using Prism (GraphPad).
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CHAPTER 3 – DISCUSSION
CAR T cell therapies are the vanguard of a new treatment paradigm in which
patients are given medications that are “alive.” The replication and survival of CAR T
cells following adoptive transfer is an important factor impacting patient outcomes.
Recent research efforts have demonstrated that T cell survival is affected by the structure
of the CAR itself, especially by the choice of costimulatory domain. At the outset of the
work reported in this thesis, the mechanism by which the costimulatory domain within a
CAR promotes T cell survival was unclear. Recent investigations into this question have
highlighted the negative effect of CD28 costimulation on CAR T cell survival. Here, for
the first time, we have demonstrated that 4-1BB costimulation directly supports CAR T
cell survival through activation of the non-canonical NF-kB (ncNF-kB) pathway, a
pathway that has never before been observed downstream of 4-1BB signaling in human
cells. We have also identified ncNF-kB-mediated Bim suppression as a possible
mechanism by which 4-1BB costimulation supports CAR T cell survival. As CAR T
cells, and other T cell-based therapies, are developed to treat other cancers and nonmalignant diseases, understanding the mechanisms impacting CAR T cell survival will be
critical in optimizing them to achieve the most durable outcomes for patients.
NOVELTY AND IMPLICATIONS
This work is the first to demonstrate that the 4-1BB intracellular domain of a
second generation CAR directly enhances CAR T cell survival. To date, studies had
associated 4-1BB with CAR T cell survival, and CD28 with early CAR T cell death
(Kawalekar et al., 2016; Long et al., 2015; Majzner and Mackall, 2019; Milone et al.,
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2009; Salter et al., 2018; Wang et al., 2015). However, these studies had only shown that
CD28 costimulation exerts a negative effect, likely due to greater phosphorylation of
downstream signaling targets and constitutive association with Lck (Feucht et al., 2019;
Long et al., 2015; Salter et al., 2018). This conclusion did not explain how 4-1BB
costimulation enhanced their expansion and persistence (Drent et al., 2019; Zhao et al.,
2015). Our work now demonstrates a direct contribution by the 4-1BB intracellular
domain to CAR T cell survival and identifies a mechanism by which it achieves this
enhanced survival: ncNF-kB signaling.
Our report is the first observation of 4-1BB-mediated non-canonical NF-kB
signaling in human T cells, and is consistent with previous data demonstrating noncanonical NF-kB signaling downstream of endogenous murine 4-1BB (McPherson et al.,
2012), but not downstream of CD28 (Li et al., 2005; Marinari et al., 2004). Additionally,
our study is the first to distinguish non-canonical from canonical NF-kB signaling
downstream of second generation CARs. Multiple reports provide conflicting data on the
role of canonical NF-kB signaling in the survival of second generation CAR T cells
(Carpenito et al., 2009; Li et al., 2018). By identifying ncNF-kB signaling as a
downstream mediator of BBz, but not 28z, CAR T cell survival, we have identified a
potentially “druggable target” to enhance the survival of non-4-1BB costimulated T cells
(Tchoghandjian et al., 2013).
Finally, we identify Bim as a novel potential regulator of CAR T cell survival.
Our data showing that 4-1BB-mediated ncNF-kB signaling suppresses Bim is consistent
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with previous reports that endogenous murine 4-1BB suppresses Bim (Sabbagh et al.,
2008), likely by cooperative action of ERK and ncNF-kB signaling (Sabbagh et al., 2008;
Vallabhapurapu et al., 2015; Wang et al., 2008). Furthermore, Bim regulates T cell
survival in vivo (Bouillet et al., 2002; Gibbons et al., 2012; Hildeman et al., 2002; Wang
et al., 2008; Wojciechowski et al., 2006; Zhu et al., 2004), supporting our hypothesis that
4-1BB-mediated ncNF-kB signaling enhances CAR T cell survival by suppressing Bim.
LIMITATIONS
Although we believe our findings are exciting and have important implications,
our study also has limitations and raises many new questions; In the spirit of selfcritique, some of these will be discussed in detail below.
One limitation of our work is that we did not demonstrate that BBz CARs directly
activate ncNF-kB signaling. A possible alternative interpretation of our data is that BBz
CARs induce more expression of OX40 and OX40L than do 28z or first generation
CARs, which may be responsible for the ncNF-kB signaling that we observed (Kondo et
al., 2007; Soroosh et al., 2006; Xiao et al., 2012). Although this indirect signaling is
possible, OX40 and OX40L tend to be expressed with even more delayed kinetics
(Soroosh et al., 2006; Takasawa et al., 2001) and would not be consistent with the more
rapid stabilization of NIK that we observed in our system (Figures 2.6A-B). Specifically,
OX40-OX40L-mediated NIK stabilization and downstream ncNF-kB signaling would
not be expected to be detectable for at least a day following CAR activation. Instead, we
observe NIK stabilization as early as 2-4 hours after receptor activation (Figures 2.6A-B)
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and peak signaling either at 12 hours in anti-CD19 BBz CAR T cells (Figures 2.6A-B).
Furthermore, TCR activation through canonical NF-kB signaling induces expression of
OX40 and OX40L (Tone et al., 2007). Yet, we see similar levels of canonical NF-kB
signaling downstream of both 28z and BBz anti-CD19 CARs (Figures 2.5A, C), but less
ncNF-kB signaling from both anti-CD19 and SS1 28z CARs compared to BBz CARs
with the same scFv’s (Figures 2.7-10). Given our findings, and that murine 4-1BB has
been observed to activate ncNF-kB (McPherson et al., 2012), it seems most likely that
the 4-1BB costimulatory domain directly activates ncNF-kB signaling.
Another issue is that although our bead-based CAR activation system allowed us
to study signaling specifically activated by CARs, it was not a high-fidelity model for
anti-CD19 CD28 CAR T cell expansion (Neelapu et al., 2017). We believe that there are
at least two factors underpinning this limitation. First, Nalm6 cells and other ALL cells
targeted by anti-CD19 CAR T cells express integrin receptor ICAM3 and have the
capacity to express CD28 ligands CD80 and CD86 upon co-culture with activated T cells
(Li et al., 2013). All of these molecules provide additional costimulatory signals not
present on the beads (Juan et al., 1994; Lenschow et al., 1996). Second, target cells
provide a transient stimulus that diminishes as they are killed by CAR T cells. In contrast,
the anti-CD19 idiotype beads provide a continuous signal to CAR T cells, which has been
shown to be detrimental particularly to CD28-costimulated CAR T cells (Long et al.,
2015). These differences are somewhat advantageous to our efforts to isolate a survival
signal triggered by the CAR. The lack of additional costimulatory signals allows for the
isolation of the CAR signal itself, and the continuous antigen interactions with the CAR
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increase our ability to detect subsequent downstream signaling. It is possible that the
diminished expansion and survival of anti-CD19 28z CAR T cells in the bead system
may mask dnNIK-mediated toxicity, but the cell death observed with the anti-CD19 28z
CAR T cells is incomplete (Figure 2.15A). We therefore should still be able to detect an
increase in cell death if dnNIK was non-specifically toxic. Additionally, dnNIKexpressing T cells, regardless of CAR, expand identically to their control counterparts in
primary cultures. This similarity strongly argues against non-specific toxicity of dnNIKexpression and supports the validity of our conclusions from the bead-based expansion
assays.
Finally, we were also unable to directly demonstrate ncNF-kB signaling-mediated
transcriptional regulation of Bim. We did attempt to do so by qPCR. However, the qPCR
primers available were not specific to each Bim isoform, and yielded conflicting results
in two attempts. Given this limitation, it was difficult to reconcile that data with our
protein expression data. Additionally, assessing RelB/p52 bcl2l11 locus binding was
technically challenging. Previous investigators have done so by ChIPseq, or ChIP-qPCR
(Vallabhapurapu et al., 2015), but this technique measures the amount of DNA bound to
either RelB or p52, and not how much RelB or p52 binds the bcl2l11 locus. Furthermore,
assessing where this dimer is bound is difficult because we would need to assess overlap
in binding of each monomer separately, and the antibodies to RelB are suboptimal.
Although we cannot exclude that ncNF-kB signaling impacts BimL and BimS expression
by some as yet undescribed post-translational mechanism, our findings are consistent
with the previously described transcriptional suppression of Bim mediated by ncNF-kB
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signaling (Vallabhapurapu et al., 2015) and ncNF-kB-mediated Bim suppression
enhancing T cell survival (Wang et al., 2008).
OUTSTANDING QUESTIONS
Having demonstrated that 4-1BB directly promotes CAR T cell survival, we
would have expected that adding the 4-1BB intracellular domain to a 28z CAR should
enhance the survival of a T cell expressing such a CAR. However, these “third
generation” CAR T cells have been largely equally or less effective than their second
generation counterparts (Carpenito et al., 2009; Majzner and Mackall, 2019; Milone et
al., 2009). This outcome is likely due to a structural limitation of these CARs. When
added in cis, in the same molecule as the CD28 domain and the z-chain, the
costimulatory domain distal to the plasma membrane does not seem to function (Guedan
et al., 2018; Ramello et al., 2019). CARs with the 4-1BB domain distal to the membrane
do not appear to associate with TRAF molecules (Ramello et al., 2019), preventing them
from transmitting a signal (Zapata et al., 2018). However, this strategy also results in
distancing the zeta chain from the CD28 domain, which may reduce the ability of Lck to
phosphorylate the CAR’s ITAMs (Feucht et al., 2019; Zhao et al., 2009). This reduction
may moderate the detrimental tonic signaling and enhanced phosphorylation cascades of
the CD28 domain of the CAR (Feucht et al., 2019; Ramello et al., 2019; Salter et al.,
2018), which might explain the superior performance of the 3rd generation CAR to the
28z CAR in a single small clinical trial (Ramos et al., 2018). Yet, these findings together
suggest that the 4-1BB domain when incorporated into a third generation CARs does not
directly enhance CAR T cell persistence.
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Even when added in trans, as achieved by co-expression of 4-1BBL in CD28
costimulated CAR T cells (Drent et al., 2019; Zhao et al., 2015), 4-1BB-mediated
survival may be mostly overshadowed by CD28 costimulated CAR-induced exhaustion
(Long et al., 2015) or AICD (Feucht et al., 2019). Furthermore, this strategy will only
cause 4-1BB activation while endogenous 4-1BB is expressed. Endogenous 4-1BB is not
expressed on resting T cells, and its expression peaks within days of T cell activation
(Pollok et al., 1993). 4-1BBL-expressing anti-CD19 28z CAR T cells rarely survive to
160 days in patients (Batlevi et al., 2019), which may be explained by our data suggesting
that constitutive ncNF-kB signaling may be critical for long-term CAR T cell persistence.
Interestingly, we observed constitutive ncNF-kB signaling in T cells expressing BBz
CARs with two different scFvs and antigen specificities (Figures 2.7-10), yet, in antiCD19 BBz CAR T cells, ERK is only phosphorylated upon CAR-ligand binding (Figures
2.5A, D-E). How can a single receptor activate one pathway constitutively, but another
only upon ligand binding?
CARs have been shown to signal in the absence of antigen, which can be
mediated by scFv-dependent CAR clustering (Long et al., 2015). The FMC63 scFv
targeting CD19 causes small punctate clusters distributed across the T cell plasma
membrane, and a more basally active CAR with a GD2-targeting scFv forms even larger
clusters that are not evenly distributed (Long et al., 2015). As SS1-scFv-containing CARs
targeting mesothelin also signal in the absence of antigen (Frigault et al., 2015), they
likely also form higher-order clusters. In both CARs used here, these clusters may
facilitate 4-1BB costimulatory domain activation, meditated by recruitment of TRAF1
89

and TRAF2. TRAF2 recruitment to crosslinked TNFRSFs retargets the E3 ubiquitin
ligases cIAP1 and cIAP2 to TRAF3, which enables the stabilization of NIK and
subsequent ncNF-kB signaling (Luftig et al., 2004; Vallabhapurapu et al., 2008).
Clustering of 4-1BB costimulated second generation CARs may mimic crosslinking of
other related TNFRSFs, thereby facilitating ncNF-kB signaling in the absence of antigen.
Unlike 4-1BB-mediated ncNF-kB signaling, TRAF-binding alone is insufficient
for 4-1BB-mediated ERK activation. 4-1BB activates ERK by coordinating both TRAF1
and Leukocyte Specific Protein 1 (LSP1) (Sabbagh et al., 2013). LSP1 is associated with
the intracellular plane of the plasma membrane in resting T cells (Matsumoto et al.,
1995). Upon TCR activation, ZAP-70 activates PKCq, which rapidly phosphorylates
LSP1 causing it to dissociate from the membrane (Matsumoto et al., 1995). Once in the
cytosol, LSP1 can activate ERK (Wu et al., 2016). As BBz CARs do not induce ZAP-70
phosphorylation and downstream PKCq activation in the absence of antigen (Salter et al.,
2018), LSP1 is likely unphosphorylated, membrane-bound, and unable to interact with
TRAF1. Upon antigen binding, BBz CARs activate ZAP-70, which would enable PKCq
phosphorylation of LSP1. Phospho-LSP1 would then be released into the cytosol, where
it could bind TRAF1 and activate ERK. This model combined with scFv-mediated
clustering suggests how BBz CARs could differentially regulate ERK and ncNF-kB
signaling.
Whereas the 4-1BB domain within the CAR may not initiate the same signals as
the endogenous 4-1BB in the absence of CD3z signaling, 4-1BB costimulated CARs do
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seem to initiate downstream signaling similarly to the endogenous 4-1BB. The 4-1BB
domain in CARs is only capable of initiating signaling and drive clonal expansion when
it can associate with TRAFs 1 and 2 (Li et al., 2018; Mamonkin et al., 2017), as is the
case for endogenous 4-1BB (Zapata et al., 2018). Upon ligand binding and TRAF2
association, endogenous 4-1BB is internalized into K63-ubiquitin-associated vesicles
(Martinez-Forero et al., 2013). Intriguingly, 4-1BB costimulated CARs also rapidly
internalize upon ligand binding and also remain stably associated with their ligand within
these vesicles (Hamieh et al., 2019). Though we did not directly observe or test whether
CAR internalization was required for 4-1BB-mediated non-canonical NF-kB signaling,
we hypothesize from the observations cited here and the similar constellations of
signaling pathways that we observed downstream of the 19BBz CAR compared to those
downstream of endogenous 4-1BB that 4-1BB costimulated CARs utilize the same
intracellular mechanisms to initiate downstream signaling as endogenous 4-1BB.
ERK and ncNF-kB signaling can cooperatively suppress Bim transcription
(Vallabhapurapu et al., 2015), so it was somewhat surprising to observe differential
regulation of the three Bim isoforms in our studies. CAR T cell expression of BimEL, the
longest and least pro-apoptotic isoform, is regulated differently than its shorter splice
variants, BimL and BimS (Figures 2.17-19). One possible mechanism by which BimEL
protein expression may be decoupled from that of BimL and BimS is highlighted in
Chapter 2: ERK-mediated degradation through binding the DEF-type domain only found
in BimEL (Clybouw et al., 2012; Ley et al., 2005; 2004; Luciano et al., 2003).
Alternatively, the three Bim isoforms are known to differ in their protein expression via
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the stabilization of BimEL and BimL isoforms by association with the cytoskeleton. BimEL
and BimL contain a dynein light chain binding domain that is spliced out of the Bims
isoform (Puthalakath et al., 1999). This association appears to stabilize these isoforms as
well as prevent them from interacting with anti-apoptotic proteins on the surface of
mitochondria (Puthalakath et al., 1999). Though this may be a mechanism by which
BimEL and BimL may be stabilized while BimS is degraded in other cell types, our data
does not reflect a decoupling in protein expression between BimL and BimS as would be
expected if the inclusion of the dynein light chain binding domain stabilized Bim
(Figures 2.17, 19). Furthermore, our findings are consistent with previous reports that
BimEL and BimL are not exclusively sequestered to the cytoskeleton in T cells (Zhu et al.,
2004), and that BimEL association with the cytoskeleton does not shield it from ERKmediated degradation (Mouhamad et al., 2004).
Though BimEL expression does not appear to be associated with ncNF-kB
signaling at any time point in CAR T cells, we were somewhat surprised that BimL and
BimS expression only increased in dnNIK-expressing anti-CD19 BBz CAR T cells
relative to their controls following CAR activation (Figures 2.17F-G). Having observed
BBz CAR-mediated tonic ncNF-kB signaling, we anticipated that Bim expression would
be increased prior to activation in dnNIK-expressing BBz CAR T cells as well. One
possible explanation is that dnNIK expression in our system may not have sufficiently
blocked basal ncNF-kB signaling to achieve a measurable reduction in Bim. The
blockade we achieve is incomplete at all timepoints, but is least consistently detectable
prior to 4-1BB costimulated CAR activation (Fig. 2.13). Therefore, dnNIK-expressing
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BBz CAR T cells may still have enough ncNF-kB signaling to mediate a similar degree
of Bim suppression as the control BBz CAR T cells.
A final puzzling finding regarding Bim regulation was that we only detected a
difference in BimL and BimS expression between 28z and BBz CAR T cells before CAR
activation (Fig. 2.19). One interpretation of this finding is that BimL and BimS expression
may not contribute to the difference in 28z and BBz CAR T cell survival following CAR
activation. However, we believe that there is an alternative explanation for this
observation in line with our hypothesis. It is possible that CD28 costimulated CAR T
cells cannot tolerate higher expression of Bim. Bim induces cell death by blocking
activity of anti-apoptotic Bcl-2-family proteins (O'Connor et al., 1998), but can also
bypass the Bcl-2-family-regulated intrinsic apoptosis pathway by interacting with Bid to
augment Fas-FasL-mediated apoptosis (Masson et al., 2011). Fas is expressed following
T cell activation during CAR T cell production (Ghassemi et al., 2018), and FasL
expression is dramatically increased by CD28-costimulated CAR activation relative to
BBz CAR activation (Feucht et al., 2019; Künkele et al., 2015). Therefore, 28z CAR T
cells may require less Bim than BBz CAR T cells to cause cell death following CAR
activation.
Increased Bim expression in the context of dnNIK inhibition of ncNF-kB
signaling could explain the dramatic loss of expansion of dnNIK-expressing anti-CD19
BBz CAR T cells, but, as Bim promotes apoptosis, we were somewhat surprised by the
small magnitude of the increase in cell death (Figure 2.14A-C). DnNIK-expressing anti93

CD19 4-1BB costimulated CAR T cells expanded 10 fold less than their control
counterparts (Fig. 2.14B), but only experienced a 6% increase in cell death (Fig. 2.14C).
Though the increase in dying cells is modest, we interpret this measure as an
“instantaneous rate” of cell death. We report dead cells as those that have lost membrane
integrity (by losing mCherry), but retain some DNA (7AAD+). These dying cells then
become debris over the course of the culture, becoming 7AAD- and falling out of the
dead cell gate. It is likely that the increased death rate has cumulative effect on
expansion, where small increases over long periods of time result in a large loss of
expansion.
Another contribution to the loss of expansion of dnNIK-expressing anti-CD19
BBz CAR T cells could be due to a reduction in cell cycle progression. There is a small
reduction in PCNA expression in dnNIK-expressing anti-CD19 BBz CAR T cells that did
not reach statistical significance (Fig. 2.14D), potentially reflecting that a smaller fraction
of cells are beyond the G1-phase of the cell cycle (Kurki et al., 1986). This reduction in
proliferation could be due to loss of ncNF-kB-mediated promotion of cell cycle
progression into S phase, a function of ncNF-kB signaling observed in multiple cancer
types (Ge et al., 2016; Uno et al., 2014). Though a reduction in proliferation could
contribute to the overall diminished expansion of dnNIK-expressing BBz CAR T cells,
this reduction was not as large or consistent as the increase in cell death in these cells or
in the referenced cancer lines. These data suggest that reduced ncNF-kB signaling
diminishes expansion primarily by increasing the frequency of cell death.
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These observations of potential downstream effectors of ncNF-kB-driven survival
highlight the need for further investigation into ncNF-kB-mediated transcriptional
regulation. Given previous reports that RelB/p52 dimers suppress gene transcription by
chromatin remodeling (Vallabhapurapu et al., 2015), future investigations into the
transcriptional impact of non-canonical NF-kB signaling in human T cells should include
not only RNAseq and ChIPseq (if specific antibodies can be employed), but also
ATACseq. Combining these three approaches could identify not only which genes
RelB/p52 dimers regulate, but also reveal how the chromatin around those genes changes
upon non-canonical NF-kB pathway activation. These hits should then be validated for
their physiological impact. Non-canonical NF-kB signaling impacts multiple cell
functions including cell cycle progression (Ge et al., 2016; Uno et al., 2014), migration
(Das et al., 2018; Duran et al., 2016; Jung et al., 2016; Tchoghandjian et al., 2013),
chemokine production (Bonizzi et al., 2004; Valiño-Rivas et al., 2016; Yang et al., 2018),
and regulatory T cell differentiation (Grinberg-Bleyer et al., 2018; Ishimaru et al., 2006;
Murray et al., 2011), none of which are well understood on a transcriptional level in
human T cells.
Based on analyses of ncNF-kB-mediated gene regulation in other cell types, we
had hypothesized that ncNF-kB signaling drives BBz CAR-associated oxidative
metabolism (Bakkar et al., 2012; Kawalekar et al., 2016; Zeng et al., 2015). We were
surprised that reducing ncNF-kB signaling did not impact anti-CD19 BBz CAR T cell
metabolism (Fig. 2.16). Recently, a study identified p38 MAPK activation of PGC1a
expression as the driver of murine 4-1BB-mediated mitochondrial biogenesis and
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oxidative metabolism (Menk et al., 2018). This finding suggests that BBz CAR signaling
may directly drive BBz CAR T cell oxidative metabolism by this mechanism. However,
oxidative metabolism was associated with human 4-1BB CAR costimulation in the
presence of IL-15 (Kawalekar et al., 2016), which itself drives oxidative metabolism in T
cells (van der Windt et al., 2012). Furthermore, CD28 costimulation imparts its own
metabolic phenotype, driving down oxidative metabolism and enhancing glycolysis
(Frauwirth et al., 2002). Future work to identify the drivers of CAR T cell oxidative
metabolism should isolate CAR signals from exogenous cytokines to deconvolute this
phenomenon.
FUTURE DIRECTIONS
The data presented here not only adds to the current understanding of how CAR T
cell signaling impacts their survival, but also elicits questions to be investigated in future
studies. We demonstrated that non-canonical NF-kB signaling is necessary for CD19
BBz CAR T cell survival, but further work is necessary to determine if it is sufficient to
enhance CAR T cell survival. Our work also suggests that tonic ncNF-kB signaling may
be sufficient or even ideal to sustain CAR T cell survival, but future investigations will
need to optimize the regulation of ncNF-kB signaling to maximize CAR T cell survival.
Both of these lines of inquiry might be accomplished by activation of ncNF-kB signaling
by an alternative approach.
One such approach to achieving tonic ncNF-kB signaling is through treatment
with SMAC mimetics, which stabilize NIK by causing the degradation of cIAP1 and
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cIAP2 (Tchoghandjian et al., 2013). Interestingly, this approach has been explored
preclinically in the context of CAR T cell therapy with a focus on using the SMAC
mimetic to downmodulate cIAP expression in the target cells to potentiate their killing by
T cell-secreted TNF-a (Michie et al., 2019). This study did not examine the potential
beneficial effects of SMAC mimetic on T cell survival, which might also have been
enhanced. Another strategy to study the effect of tonic ncNF-kB signaling alone might be
to transduce T cells with proteins that would constitutively activate the pathway, such as
an autonomously clustering transmembrane protein containing only the 4-1BB
intracellular domain or a constitutively active, non-degradable NIK mutant (Liu et al.,
2012; Xiu et al., 2018). Both the pharmacologic and genetic approaches should be
pursued in the context of either an ICOS or “tuned” CD28 CAR, so as to diminish the
toxic effects of tonic or excessive ITAM-mediated signaling. Combining one of these
CARs with ncNF-kB signaling may also be a useful translational strategy to improve
activity against tumors that can down-regulate the CAR-targeted antigen or create an
immunosuppressive environment, as these CAR T cells are more sensitive to low antigen
density and less sensitive to T regulatory cell-mediated suppression than the BBz CAR
alone (Golumba-Nagy et al., 2018; Majzner et al., 2018; Priceman et al., 2018; Walker et
al., 2017). These CAR T cells, augmented by ncNF-kB signaling, could both resist these
suppressive features while also potentially resisting cell death.
If Bim suppression represents the final “common” pathway to achieve survival in
BBz CAR T cells, another approach to enhance CAR T cell survival might be to suppress
BimL and BimS expression. Such work would clarify whether BimL and BimS expression
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causes CAR T cell death, or is merely inversely associated with survival. However,
complete Bim knockout may not be a fruitful strategy, as loss of Bim allows Bcl-2 to
block IP3R-mediated calcium release, thereby blunting T cell activation (Ludwinski et al.,
2009). One strategy to avoid this Bcl-2 dysregulation would be to replace the existing
bcl2l11 gene with a modified bcl2l11 sequence that cannot be spliced into its smaller
isoforms. Given that BimEL is repressed by ERK (Clybouw et al., 2012; Ley et al., 2004),
such a strategy could maintain diminished Bim levels after CAR activation, but avoid
aberrant Bcl-2-mediated IP3R blockade. This combination may be sufficient to maintain
CAR T cell activation, while enhancing survival.
How can we incorporate these data into optimizing future CAR designs? CARs
need to be optimized for each application. For example, years-long CAR T cell
persistence appears to be critical for durable remission in pediatric ALL, but curiously,
not for diffuse large B cell lymphoma (DLBCL) (Majzner and Mackall, 2019). This
difference may be due to the high rate of cancer stem cells found among ALL cells (Rehe
et al., 2013), whereas DLBCL appears to have relatively few, if any (Husby and
Grønbæk, 2017). Sustained control of tumors supported by a cancer stem cell population
may require persistent CAR T cells, the creation of which may be aided by minimizing
ITAM-mediated signaling and adding ncNF-kB signaling.
With CARs now targeting autoreactive B cells (Ellebrecht et al., 2016),
optimizing them for non-malignant diseases may require a contrary approach: selection
for short-lived CAR T cells. Diseases such as pemphigus vulgaris are caused by the
production of autoreactive antibodies, in this case, targeting desmoglein 3 (Payne et al.,
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2004). Unlike malignant B cells, these cells are not transformed and do not proliferate
indefinitely (Hammers et al., 2015). Therefore, eliminating them is unlikely to require a
persistent CAR T cell population. Furthermore, CAR T cells are not without the capacity
to cause toxicity themselves (Davila et al., 2014; Morgan et al., 2013; Smith and Venella,
2017; Sterner et al., 2019), so optimizing them to be effective and short-lived in cases
like this could be ideal.
MODEL
Our findings inform an updated model explaining the association between 4-1BB
costimulation and CAR T cell survival. 4-1BB drives less or equal phosphorylation of a
number of downstream signaling targets compared to CD28 (Salter et al., 2018), which
likely potentiates CAR T cell death through FAS-FASL interactions (Feucht et al., 2019;
Künkele et al., 2015). We observed that 4-1BB also directly enhances CAR T cell
survival by activation of non-canonical NF-kB signaling, both basally and, in the case of
the anti-CD19 CAR, upon ligand binding. This enhancement in survival was associated
with a decrease in expression of the most pro-apoptotic isoforms of Bim, the expression
of which is likely restricted by RelB/p52 dimer-mediated HDAC4 recruitment to the
bcl2l11 locus (Vallabhapurapu et al., 2015). HDAC4 deacetylates the histones bound to
the bcl2l11 locus, thereby rendering the locus inaccessible to RNA polymerase
(Vallabhapurapu et al., 2015). Bim expression may be further suppressed upon CAR
ligand binding, which activates ERK1/2. ERK1 can phosphorylate RelB in cells with
active ncNF-kB signaling, thereby enhancing HDAC4 recruitment and ncNF-kBmediated Bim suppression (Vallabhapurapu et al., 2015). NcNF-kB signaling may also
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impact CAR T cell survival by suppressing the expression of other pro-apoptotic genes,
such as BMF (Vallabhapurapu et al., 2015), and influence CAR T cell function by direct
interaction of NIK with mitochondria (Jung et al., 2016). NIK, independently of
downstream ncNF-kB, directly binds to mitochondria, thereby driving mitochondria to
the cell periphery. This change in mitochondrial localization enhances tumor cell
invasion into surrounding tissues (Jung et al., 2016). Therefore, ncNF-kB signaling not
only enhances 4-1BB-costimulated CAR T cell survival, but may also contribute to the
trafficking of these CAR T cells into sites containing CAR antigen. In addition to
describing a new mechanism of 4-1BB-mediated CAR T cell survival, the work
presented here has opened numerous avenues for further study to refine and improve our
understanding of CAR T cell biology and the ncNF-kB pathway.
The work presented in this thesis and many of the future directions stemming
from it employ chimeric antigen receptors as tools to study T cell biology, as did those
who created the first CARs. Since their invention, CARs have brought about a paradigm
shift in therapeutic development. CAR T cell therapies have not only achieved dramatic
results for patients for whom no further intervention existed, but have also highlighted the
need for an even deeper understanding of T cell biology in the instances where CAR T
cells have failed. These failures inspired this return to the bench, where CARs were first
created. Our hope is that this work informs the enhancement of future T cell therapies,
thereby continuing the iterative cycle of therapeutic development: from bench to bedside,
and back again.

100

BIBLIOGRAPHY
Ajina, A., and Maher, J. (2018). Strategies to Address Chimeric Antigen Receptor Tonic
Signaling. Mol. Cancer Ther. 17, 1795–1815.
Altenschmidt, U., Klundt, E., and Groner, B. (1997). Adoptive transfer of in vitrotargeted, activated T lymphocytes results in total tumor regression. The Journal of
Immunology 159, 5509–5515.
Alvarez-Vallina, L., and Hawkins, R.E. (1996). Antigen-specific targeting of CD28mediated T cell co-stimulation using chimeric single-chain antibody variable fragmentCD28 receptors. Eur. J. Immunol. 26, 2304–2309.
Arch, R.H., and Thompson, C.B. (1998). 4-1BB and Ox40 are members of a tumor
necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptorassociated factors and activate nuclear factor kappaB. Molecular and Cellular Biology 18,
558–565.
Aruffo, A., and Seed, B. (1987). Molecular cloning of a CD28 cDNA by a highefficiency COS cell expression system. Proc. Natl. Acad. Sci. U.S.a. 84, 8573–8577.
Bakkar, N., Ladner, K., Canan, B.D., Liyanarachchi, S., Bal, N.C., Pant, M., Periasamy,
M., Li, Q., Janssen, P.M.L., and Guttridge, D.C. (2012). IKKα and alternative NF-κB
regulate PGC-1β to promote oxidative muscle metabolism. J. Cell Biol. 196, 497–511.
Barnes, D.W., and Loutit, J.F. (1957). Treatment of murine leukaemia with x-rays and
homologous bone marrow. II. Br. J. Haematol. 3, 241–252.
Barnes, D.W., Corp, M.J., Loutit, J.F., and Neal, F.E. (1956). Treatment of murine
leukaemia with X rays and homologous bone marrow; preliminary communication. Br
Med J 2, 626–627.
Barrett, D.M., Singh, N., Liu, X., Jiang, S., June, C.H., Grupp, S.A., and Zhao, Y. (2014).
Relation of clinical culture method to T-cell memory status and efficacy in xenograft
models of adoptive immunotherapy. Cytotherapy 16, 619–630.
Bashour, K.T., Tsai, J., Shen, K., Lee, J.-H., Sun, E., Milone, M.C., Dustin, M.L., and
Kam, L.C. (2014). Cross talk between CD3 and CD28 is spatially modulated by protein
lateral mobility. Molecular and Cellular Biology 34, 955–964.
Batlevi, C.L., Palomba, M.L., Park, J., Mead, E., Santomasso, B., Riviere, I., Wang, X.,
Senechal, B., Furman, R., Yang, J., et al. (2019). PHASE I CLINICAL TRIAL OF
CD19‐TARGETED 19‐28Z/4‐1BBL “ARMORED” CAR T CELLS IN PATIENTS
WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER
TRANSFORMATION. Hematological Oncology 37, 166–167.
101

Becker, M.L., Near, R., Mudgett-Hunter, M., Margolies, M.N., Kubo, R.T., Kaye, J., and
Hedrick, S.M. (1989). Expression of a hybrid immunoglobulin-T cell receptor protein in
transgenic mice. Cell 58, 911–921.
Bertram, E.M., Lau, P., and Watts, T.H. (2002). Temporal segregation of 4-1BB versus
CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the
primary response and regulates the size of the T cell memory response following
influenza infection. The Journal of Immunology 168, 3777–3785.
Beug, S.T., Beauregard, C.E., Healy, C., Sanda, T., St-Jean, M., Chabot, J., Walker, D.E.,
Mohan, A., Earl, N., Lun, X., et al. (2017). Smac mimetics synergize with immune
checkpoint inhibitors to promote tumour immunity against glioblastoma. Nature
Communications 8.
Bitra, A., Doukov, T., Croft, M., and Zajonc, D.M. (2018). Crystal structures of the
human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization
as a potential signaling amplifier. J. Biol. Chem. jbc.RA118.003176.
Boise, L.H., Minn, A.J., Noel, P.J., June, C.H., Accavitti, M.A., Lindsten, T., and
Thompson, C.B. (1995). CD28 costimulation can promote T cell survival by enhancing
the expression of Bcl-xL. Immunity 3, 87–98.
Bonizzi, G., Bebien, M., Otero, D.C., Johnson-Vroom, K.E., Cao, Y., Vu, D., Jegga,
A.G., Aronow, B.J., Ghosh, G., Rickert, R.C., et al. (2004). Activation of IKKalpha
target genes depends on recognition of specific kappaB binding sites by RelB:p52
dimers. The EMBO Journal 23, 4202–4210.
Boomer, J.S., and Green, J.M. (2010). An enigmatic tail of CD28 signaling. Cold Spring
Harb Perspect Biol 2, a002436–a002436.
Bordon, Y. (2012). Immunometabolism: IL-15 provides breathing space for memory.
Nat. Rev. Immunol. 12, 76–77.
Bouchkouj, N., Kasamon, Y.L., de Claro, R.A., George, B., Lin, X., Lee, S., Blumenthal,
G.M., Bryan, W., McKee, A.E., and Pazdur, R. (2019). FDA Approval Summary:
Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma. Clinical
Cancer Research 25, 1702–1708.
Bouillet, P., Purton, J.F., Godfrey, D.I., Zhang, L.-C., Coultas, L., Puthalakath, H.,
Pellegrini, M., Cory, S., Adams, J.M., and Strasser, A. (2002). BH3-only Bcl-2 family
member Bim is required for apoptosis of autoreactive thymocytes. Nature 415, 922–926.
Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., QuintásCardama, A., Larson, S.M., and Sadelain, M. (2007). Genetically targeted T cells
eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research
13, 5426–5435.
102

Brocker, T., and Karjalainen, K. (1995). Signals through T cell receptor-zeta chain alone
are insufficient to prime resting T lymphocytes. J. Exp. Med. 181, 1653–1659.
Bu, J.Y., Shaw, A.S., and Chan, A.C. (1995). Analysis of the interaction of ZAP-70 and
syk protein-tyrosine kinases with the T-cell antigen receptor by plasmon resonance. Proc.
Natl. Acad. Sci. U.S.a. 92, 5106–5110.
Cannons, J.L., Choi, Y., and Watts, T.H. (2000). Role of TNF Receptor-Associated
Factor 2 and p38 Mitogen-Activated Protein Kinase Activation During 4-1BB-Dependent
Immune Response. The Journal of Immunology 165, 6193–6204.
Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M.,
Varela-Rohena, A., Haines, K.M., Heitjan, D.F., Albelda, S.M., et al. (2009). Control of
large, established tumor xenografts with genetically retargeted human T cells containing
CD28 and CD137 domains. Proceedings of the National Academy of Sciences 106,
3360–3365.
Chan, A.C., Dalton, M., Johnson, R., Kong, G.H., Wang, T., Thoma, R., and Kurosaki, T.
(1995). Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is
required for lymphocyte antigen receptor function. The EMBO Journal 14, 2499–2508.
Chan, A.C., Iwashima, M., Turck, C.W., and Weiss, A. (1992). ZAP-70: A 70 kd proteintyrosine kinase that associates with the TCR ζ chain. Cell 71, 649–662.
Chen, Y.Y. (2015). Efficient Gene Editing in Primary Human T Cells. Trends in
Immunology 36, 667–669.
Claudio, E., Brown, K., Park, S., Wang, H., and Siebenlist, U. (2002). BAFF-induced
NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3,
958–965.
Clybouw, C., Merino, D., Nebl, T., Masson, F., Robati, M., O'Reilly, L., Hübner, A.,
Davis, R.J., Strasser, A., and Bouillet, P. (2012). Alternative splicing of Bim and Erkmediated Bim(EL) phosphorylation are dispensable for hematopoietic homeostasis in
vivo. Cell Death Differ. 19, 1060–1068.
Coope, H.J., Atkinson, P.G.P., Huhse, B., Belich, M., Janzen, J., Holman, M.J., Klaus,
G.G.B., Johnston, L.H., and Ley, S.C. (2002). CD40 regulates the processing of NF‐κB2
p100 to p52. The EMBO Journal 21, 5375–5385.
Cooper, L.J.N., Topp, M.S., Serrano, L.M., Gonzalez, S., Chang, W.-C., Naranjo, A.,
Wright, C., Popplewell, L., Raubitschek, A., Forman, S.J., et al. (2003). T-cell clones can
be rendered specific for CD19: toward the selective augmentation of the graft-versus-Blineage leukemia effect. Blood 101, 1637–1644.

103

Cormier, F., Monjanel, H., Fabre, C., Billot, K., Sapharikas, E., Chereau, F., Bordereaux,
D., Molina, T.J., Avet-Loiseau, H., and Baud, V. (2013). Frequent engagement of RelB
activation is critical for cell survival in multiple myeloma. PLoS ONE 8, e59127.
D'Souza, W.N., Chang, C.-F., Fischer, A.M., Li, M., and Hedrick, S.M. (2008). The Erk2
MAPK regulates CD8 T cell proliferation and survival. J. Immunol. 181, 7617–7629.
Das, R., Coupar, J., Clavijo, P.E., Saleh, A., Cheng, T.-F., Yang, X., Chen, J., Van Waes,
C., and Chen, Z. (2018). Lymphotoxin-β receptor-NIK signaling induces alternative
RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in
head and neck cancer. Mol. Carcinog.
Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S.,
Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014). Efficacy and toxicity
management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci
Transl Med 6, 224ra25–224ra25.
DeBenedette, M.A., Shahinian, A., Mak, T.W., and Watts, T.H. (1997). Costimulation of
CD28- T lymphocytes by 4-1BB ligand. The Journal of Immunology 158, 551–559.
Deeks, S.G., Wagner, B., Anton, P.A., Mitsuyasu, R.T., Scadden, D.T., Huang, C.,
Macken, C., Richman, D.D., Christopherson, C., June, C.H., et al. (2002). A phase II
randomized study of HIV-specific T-cell gene therapy in subjects with undetectable
plasma viremia on combination antiretroviral therapy. Mol Ther 5, 788–797.
Dougan, M., Dougan, S., Slisz, J., Firestone, B., Vanneman, M., Draganov, D., Goyal,
G., Li, W., Neuberg, D., Blumberg, R., et al. (2010). IAP inhibitors enhance costimulation to promote tumor immunity. Journal of Experimental Medicine 207, 2195–
2206.
Drent, E., Poels, R., Ruiter, R., van de Donk, N.W.C.J., Zweegman, S., Yuan, H., de
Bruijn, J., Sadelain, M., Lokhorst, H.M., Groen, R., et al. (2019). Combined CD28 and 41BB costimulation potentiates affinity-tuned Chimeric Antigen Receptor-engineered T
cells. Clinical Cancer Research clincanres.2559.2018.
Duran, C.L., Lee, D.W., Jung, J.-U., Ravi, S., Pogue, C.B., Toussaint, L.G., Bayless, K.J.,
and Sitcheran, R. (2016). NIK regulates MT1-MMP activity and promotes glioma cell
invasion independently of the canonical NF-κB pathway. Oncogenesis 5, e231.
Eliopoulos, A.G., Caamano, J.H., Flavell, J., Reynolds, G.M., Murray, P.G., Poyet, J.-L.,
and Young, L.S. (2003). Epstein-Barr virus-encoded latent infection membrane protein 1
regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMOindependent signalling pathway. Oncogene 22, 7557–7569.
Ellebrecht, C.T., Bhoj, V.G., Nace, A., Choi, E.J., Mao, X., Cho, M.J., Di Zenzo, G.,
Lanzavecchia, A., Seykora, J.T., Cotsarelis, G., et al. (2016). Reengineering chimeric
104

antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–
184.
Eshhar, Z., Waks, T., Gross, G., and Schindler, D.G. (1993). Specific activation and
targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and T-cell
receptors. Proc. Natl. Acad. Sci. U.S.a. 90, 720–724.
Feins, S., Kong, W., Williams, E.F., Milone, M.C., and Fraietta, J.A. (2019). An
introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human
cancer. Am. J. Hematol. 94, S3–S9.
Festjens, N., Vanden Berghe, T., Cornelis, S., and Vandenabeele, P. (2007). RIP1, a
kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 14, 400–410.
Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A.,
Hamieh, M., and Sadelain, M. (2019). Calibration of CAR activation potential directs
alternative T cell fates and therapeutic potency. Nat Med 25, 82–88.
Finney, H.M., Lawson, A.D., Bebbington, C.R., and Weir, A.N. (1998). Chimeric
receptors providing both primary and costimulatory signaling in T cells from a single
gene product. The Journal of Immunology 161, 2791–2797.
Fraietta, J.A., Lacey, S.F., Orlando, E.J., Pruteanu-Malinici, I., Gohil, M., Lundh, S.,
Boesteanu, A.C., Wang, Y., O'Connor, R.S., Hwang, W.-T., et al. (2018). Determinants
of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of
chronic lymphocytic leukemia. Nat Med 24, 563–571.
Frauwirth, K.A., Riley, J.L., Harris, M.H., Parry, R.V., Rathmell, J.C., Plas, D.R.,
Elstrom, R.L., June, C.H., and Thompson, C.B. (2002). The CD28 signaling pathway
regulates glucose metabolism. Immunity 16, 769–777.
Frigault, M.J., Lee, J., Basil, M.C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar,
O.U., Guedan, S., McGettigan, S.E., Posey, A.D., et al. (2015). Identification of chimeric
antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer
Immunol Res 3, 356–367.
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R.,
Gostick, E., Yu, Z., Carpenito, C., et al. (2011). A human memory T cell subset with
stem cell-like properties. Nat Med 17, 1290–1297.
Ge, Q.-L., Liu, S.-H., Ai, Z.-H., Tao, M.-F., Ma, L., Wen, S.-Y., Dai, M., Liu, F., Liu, H.S., Jiang, R.-Z., et al. (2016). RelB/NF-κB links cell cycle transition and apoptosis to
endometrioid adenocarcinoma tumorigenesis. Cell Death Dis 7, e2402–e2402.

105

Ghassemi, S., Nunez-Cruz, S., O'Connor, R.S., Fraietta, J.A., Patel, P.R., Scholler, J.,
Barrett, D.M., Lundh, S.M., Davis, M.M., Bedoya, F., et al. (2018). Reducing Ex Vivo
Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T
Cells. Cancer Immunol Res 6, 1100–1109.
Giardino Torchia, M.L., Munitic, I., Castro, E., Herz, J., McGavern, D.B., and Ashwell,
J.D. (2015). c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and
CD8(+) memory T-cell survival. Eur. J. Immunol. 45, 2672–2682.
Gibbons, R.M., Liu, X., Pulko, V., Harrington, S.M., Krco, C.J., Kwon, E.D., and Dong,
H. (2012). B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by
upregulating Bim. Oncoimmunology 1, 1061–1073.
Gilbreth, R.N., Oganesyan, V.Y., Amdouni, H., Novarra, S., Grinberg, L., Barnes, A.,
and Baca, M. (2018a). Crystal structure of the human 4-1BB/4-1BBL complex. J. Biol.
Chem. jbc.RA118.002803.
Gilbreth, R.N., Oganesyan, V.Y., Amdouni, H., Novarra, S., Grinberg, L., Barnes, A.,
and Baca, M. (2018b). Crystal structure of the human 4-1BB/4-1BBL complex. J. Biol.
Chem. jbc.RA118.002803.
Goldman, J.M., Gale, R.P., Horowitz, M.M., Biggs, J.C., Champlin, R.E., Gluckman, E.,
Hoffmann, R.G., Jacobsen, S.J., Marmont, A.M., and McGlave, P.B. (1988). Bone
marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased
risk for relapse associated with T-cell depletion. Ann. Intern. Med. 108, 806–814.
Golumba-Nagy, V., Kuehle, J., Hombach, A.A., and Abken, H. (2018). CD28-ζ CAR T
Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an
Engineered IL-7 Autocrine Loop. Mol Ther 26, 2218–2230.
Grinberg-Bleyer, Y., Caron, R., Seeley, J.J., De Silva, N.S., Schindler, C.W., Hayden,
M.S., Klein, U., and Ghosh, S. (2018). The Alternative NF-κB Pathway in Regulatory T
Cell Homeostasis and Suppressive Function. J. Immunol. 200, ji1800042–ji1802371.
Gross, G., Waks, T., and Eshhar, Z. (1989). Expression of immunoglobulin-T-cell
receptor chimeric molecules as functional receptors with antibody-type specificity. Proc.
Natl. Acad. Sci. U.S.a. 86, 10024–10028.
Gubser, P.M., Bantug, G.R., Razik, L., Fischer, M., Dimeloe, S., Hoenger, G., Durovic,
B., Jauch, A., and Hess, C. (2013). Rapid effector function of memory CD8+ T cells
requires an immediate-early glycolytic switch. Nat. Immunol. 14, 1064–1072.
Guedan, S., Posey, A.D., Shaw, C., Wing, A., Da, T., Patel, P.R., McGettigan, S.E.,
Casado-Medrano, V., Kawalekar, O.U., Uribe-Herranz, M., et al. (2018). Enhancing
CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3.
106

Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S.J.C., Giavridis, T., MansillaSoto, J., Eyquem, J., Zhao, Z., Whitlock, B.M., Miele, M.M., et al. (2019). CAR T cell
trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112–
116.
Hammers, C.M., Chen, J., Lin, C., Kacir, S., Siegel, D.L., Payne, A.S., and Stanley, J.R.
(2015). Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over
years. J. Invest. Dermatol. 135, 742–749.
Harding, F.A., McArthur, J.G., Gross, J.A., Raulet, D.H., and Allison, J.P. (1992). CD28mediated signalling co-stimulates murine T cells and prevents induction of anergy in Tcell clones. Nature 356, 607–609.
Harris, D.T., and Kranz, D.M. (2015). Adoptive T Cell Therapies: A Comparison of T
Cell Receptors and Chimeric Antigen Receptors. Trends Pharmacol. Sci. 1–11.
Hauer, J., Püschner, S., Ramakrishnan, P., Simon, U., Bongers, M., Federle, C., and
Engelmann, H. (2005). TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an
inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by
TRAF-binding TNFRs. Proc. Natl. Acad. Sci. U.S.a. 102, 2874–2879.
Haynes, N.M., Snook, M.B., Trapani, J.A., Cerruti, L., Jane, S.M., Smyth, M.J., and
Darcy, P.K. (2001). Redirecting Mouse CTL Against Colon Carcinoma: Superior
Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs
FcεRI-γ. The Journal of Immunology 166, 182–187.
Hedrick, S.M., Nielsen, E.A., Kavaler, J., Cohen, D.I., and Davis, M.M. (1984).
Sequence relationships between putative T-cell receptor polypeptides and
immunoglobulins. Nature 308, 153–158.
Hege, K.M., and Roberts, M.R. (1996). T-cell gene therapy. Curr. Opin. Biotechnol. 7,
629–634.
Hellstrom, I., Hellstrom, K.E., Pierce, G.E., and Yang, J.P. (1968). Cellular and humoral
immunity to different types of human neoplasms. Nature 220, 1352–1354.
Hellström, I.E., Hellstrom, K.E., Pierce, G.E., and Bill, A.H. (1968). Demonstration of
cell-bound and humoral immunity against neuroblastoma cells. Proc. Natl. Acad. Sci.
U.S.a. 60, 1231–1238.
Hemmings, B.A., and Restuccia, D.F. (2012). PI3K-PKB/Akt pathway. Cold Spring Harb
Perspect Biol 4, a011189.
Hendriks, J., Xiao, Y., Rossen, J.W.A., van der Sluijs, K.F., Sugamura, K., Ishii, N., and
Borst, J. (2005). During viral infection of the respiratory tract, CD27, 4-1BB, and OX40
107

collectively determine formation of CD8+ memory T cells and their capacity for
secondary expansion. The Journal of Immunology 175, 1665–1676.
Hernandez-Chacon, J.A., Li, Y., Wu, R.C., Bernatchez, C., Wang, Y., Weber, J.S., Hwu,
P., and Radvanyi, L.G. (2011). Costimulation through the CD137/4-1BB pathway
protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell
death and enhances antitumor effector function. J. Immunother. 34, 236–250.
Hildeman, D.A., Zhu, Y., Mitchell, T.C., Bouillet, P., Strasser, A., Kappler, J., and
Marrack, P. (2002). Activated T cell death in vivo mediated by proapoptotic bcl-2 family
member bim. Immunity 16, 759–767.
Hockings, C., Alsop, A.E., Fennell, S.C., Lee, E.F., Fairlie, W.D., Dewson, G., and
Kluck, R.M. (2018). Mcl-1 and Bcl-xLsequestration of Bak confers differential resistance
to BH3-only proteins. Cell Death Differ. 15, 1–732.
Holdorf, A.D., Green, J.M., Levin, S.D., Denny, M.F., Straus, D.B., Link, V.,
Changelian, P.S., Allen, P.M., and Shaw, A.S. (1999). Proline residues in CD28 and the
Src homology (SH)3 domain of Lck are required for T cell costimulation. J. Exp. Med.
190, 375–384.
Hombach, A.A., and Abken, H. (2011). Costimulation by chimeric antigen receptors
revisited the T cell antitumor response benefits from combined CD28‐OX40 signalling.
International Journal of Cancer 129, 2935–2944.
Hombach, A., Wieczarkowiecz, A., Marquardt, T., Heuser, C., Usai, L., Pohl, C., Seliger,
B., and Abken, H. (2001). Tumor-Specific T Cell Activation by Recombinant
Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously
Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined
CD28/CD3ζ Signaling Receptor Molecule. The Journal of Immunology 167, 6123–6131.
House, C.D., Grajales, V., Ozaki, M., Jordan, E., Wubneh, H., Kimble, D.C., James,
J.M., Kim, M.K., and Annunziata, C.M. (2018). IΚΚε cooperates with either MEK or
non-canonical NF-kB driving growth of triple-negative breast cancer cells in different
contexts. BMC Cancer 18, 595.
Hurtado, J.C., Kim, Y.J., and Kwon, B.S. (1997). Signals through 4-1BB are
costimulatory to previously activated splenic T cells and inhibit activation-induced cell
death. The Journal of Immunology 158, 2600–2609.
Husby, S., and Grønbæk, K. (2017). Mature lymphoid malignancies: origin, stem cells,
and chronicity. Blood Adv 1, 2444–2455.
Hwu, P., Shafer, G.E., Treisman, J., Schindler, D.G., Gross, G., Cowherd, R., Rosenberg,
S.A., and Eshhar, Z. (1993). Lysis of ovarian cancer cells by human lymphocytes
108

redirected with a chimeric gene composed of an antibody variable region and the Fc
receptor gamma chain. J. Exp. Med. 178, 361–366.
Hwu, P., Yang, J.C., Cowherd, R., Treisman, J., Shafer, G.E., Eshhar, Z., and Rosenberg,
S.A. (1995). In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell
receptor genes. Cancer Research 55, 3369–3373.
Imai, C., Mihara, K., Andreansky, M., Nicholson, I.C., Pui, C.-H., Geiger, T.L., and
Campana, D. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent
cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676–684.
Irving, B.A., and Weiss, A. (1991). The cytoplasmic domain of the T cell receptor ζ chain
is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891–
901.
Ishimaru, N., Kishimoto, H., Hayashi, Y., and Sprent, J. (2006). Regulation of naive T
cell function by the NF-kappaB2 pathway. Nat. Immunol. 7, 763–772.
J C Mottram, M.B.L., and Sidney Russ, D.S.L. (1917). Observations and experiments on
the susceptibility and immunity of rats towards Jensen’s Rat Sarcoma. Proc R Soc Lond
B Biol Sci 90, 1–33.
Jang, I.K., Lee, Z.H., Kim, Y.J., Kim, S.H., and Kwon, B.S. (1998). Human 4-1BB
(CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B. Biochem.
Biophys. Res. Commun. 242, 613–620.
Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S.,
Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., et al. (2009). Gene therapy
with human and mouse T-cell receptors mediates cancer regression and targets normal
tissues expressing cognate antigen. Blood 114, 535–546.
Jones, R.G., Elford, A.R., Parsons, M.J., Wu, L., Krawczyk, C.M., Yeh, W.-C., Hakem,
R., Rottapel, R., Woodgett, J.R., and Ohashi, P.S. (2002). CD28-dependent activation of
protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing
signaling complex assembly. J. Exp. Med. 196, 335–348.
Juan, M., Viñas, O., Pino-Otín, M.R., Places, L., Martínez-Cáceres, E., Barceló, J.J.,
Miralles, A., Vilella, R., la Fuente, de, M.A., and Vives, J. (1994). CD50 (intercellular
adhesion molecule 3) stimulation induces calcium mobilization and tyrosine
phosphorylation through p59fyn and p56lck in Jurkat T cell line. J. Exp. Med. 179, 1747–
1756.
June, C.H., Ledbetter, J.A., Gillespie, M.M., Lindsten, T., and Thompson, C.B. (1987).
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant
interleukin 2 gene expression. Molecular and Cellular Biology 7, 4472–4481.
109

June, C.H., Ledbetter, J.A., Linsley, P.S., and Thompson, C.B. (1990). Role of the CD28
receptor in T-cell activation. Immunol. Today 11, 211–216.
Jung, J.-U., Ravi, S., Lee, D.W., McFadden, K., Kamradt, M.L., Toussaint, L.G., and
Sitcheran, R. (2016). NIK/MAP3K14 Regulates Mitochondrial Dynamics and
Trafficking to Promote Cell Invasion. Curr. Biol. 26, 3288–3302.
Kaech, S.M., and Ahmed, R. (2001). Memory CD8+ T cell differentiation: initial antigen
encounter triggers a developmental program in naïve cells. Nat. Immunol. 2, 415–422.
Kane, L.P., Lin, J., and Weiss, A. (2002). It's all Rel-ative: NF-κB and CD28
costimulation of T-cell activation. Trends in Immunology 23, 413–420.
Kawalekar, O.U., O'Connor, R.S., Fraietta, J.A., Guo, L., McGettigan, S.E., Posey, A.D.,
Patel, P.R., Guedan, S., Scholler, J., Keith, B., et al. (2016). Distinct Signaling of
Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory
Development in CAR T Cells. Immunity 44, 380–390.
Kellock, T., Chambers, H., and Russ, S. (1922). An Attempt To Procure Immunity To
Malignant Disease In Man. The Lancet 199, 217–219.
Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A.,
White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L., et al. (2006). A Phase I
Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer.
Clinical Cancer Research 12, 6106–6115.
Khoshnan, A., Tindell, C., Laux, I., Bae, D., Bennett, B., and Nel, A.E. (2000). The NFkappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of
the CD28 receptor in primary human CD4+ lymphocytes. The Journal of Immunology
165, 1743–1754.
Kim, H.H., Tharayil, M., and Rudd, C.E. (1998). Growth factor receptor-bound protein 2
SH2/SH3 domain binding to CD28 and its role in co-signaling. Journal of Biological
Chemistry 273, 296–301.
Kim, J.-Y., Morgan, M., Kim, D.-G., Lee, J.-Y., Bai, L., Lin, Y., Liu, Z.-G., and Kim, Y.S. (2011). TNFα induced noncanonical NF-κB activation is attenuated by RIP1 through
stabilization of TRAF2. Journal of Cell Science 124, 647–656.
King, P.D., Sadra, A., Teng, J.M., Xiao-Rong, L., Han, A., Selvakumar, A., August, A.,
and Dupont, B. (1997). Analysis of CD28 cytoplasmic tail tyrosine residues as regulators
and substrates for the protein tyrosine kinases, EMT and LCK. The Journal of
Immunology 158, 580–590.
Klebanoff, C.A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A.R.,
Finkelstein, S.E., Palmer, D.C., Antony, P.A., Hwang, S.T., Rosenberg, S.A., et al.
110

(2005). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor
immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U.S.a. 102,
9571–9576.
Kochenderfer, J.N., Feldman, S.A., Zhao, Y., Xu, H., Black, M.A., Morgan, R.A.,
Wilson, W.H., and Rosenberg, S.A. (2009). Construction and preclinical evaluation of an
anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689–702.
Kondo, K., Okuma, K., Tanaka, R., Zhang, L.F., Kodama, A., Takahashi, Y., Yamamoto,
N., Ansari, A.A., and Tanaka, Y. (2007). Requirements for the functional expression of
OX40 ligand on human activated CD4+ and CD8+ T cells. Hum. Immunol. 68, 563–571.
Kowolik, C.M., Topp, M.S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith,
D.D., Forman, S.J., Jensen, M.C., and Cooper, L.J.N. (2006). CD28 costimulation
provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence
and antitumor efficacy of adoptively transferred T cells. Cancer Research 66, 10995–
11004.
Krause, A., Guo, H.F., Latouche, J.B., Tan, C., Cheung, N.K., and Sadelain, M. (1998).
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in
genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619–
626.
Krummel, M.F., Heath, W.R., and Allison, J. (1999). Differential coupling of second
signals for cytotoxicity and proliferation in CD8+ T cell effectors: amplification of the
lytic potential by B7. The Journal of Immunology 163, 2999–3006.
Kurki, P., Vanderlaan, M., Dolbeare, F., Gray, J., and Tan, E.M. (1986). Expression of
proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp. Cell Res.
166, 209–219.
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F.,
and Kurosawa, Y. (1987). Expression of chimeric receptor composed of
immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem.
Biophys. Res. Commun. 149, 960–968.
Künkele, A., Johnson, A.J., Rolczynski, L.S., Chang, C.A., Hoglund, V., Kelly-Spratt,
K.S., and Jensen, M.C. (2015). Functional Tuning of CARs Reveals Signaling Threshold
above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasLDependent AICD. Cancer Immunol Res 3, 368–379.
Lee, H.-W., Park, S.-J., Choi, B.K., Kim, H.H., Nam, K.-O., and Kwon, B.S. (2002). 41BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL
and Bfl-1. The Journal of Immunology 169, 4882–4888.

111

Lenschow, D.J., Walunas, T.L., and Bluestone, J.A. (1996). CD28/B7 system of T cell
costimulation. Annu. Rev. Immunol. 14, 233–258.
Levine, B.L., Cotte, J., Small, C.C., Carroll, R.G., Riley, J.L., Bernstein, W.B., Van
Epps, D.E., Hardwick, R.A., and June, C.H. (1998). Large-scale production of CD4+ T
cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 7, 437–
448.
Ley, R., Ewings, K.E., Hadfield, K., Howes, E., Balmanno, K., and Cook, S.J. (2004).
Extracellular signal-regulated kinases 1/2 are serum-stimulated “Bim(EL) kinases” that
bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. Journal
of Biological Chemistry 279, 8837–8847.
Ley, R., Hadfield, K., Howes, E., and Cook, S.J. (2005). Identification of a DEF-type
docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation
and turnover of the BH3-only protein BimEL. Journal of Biological Chemistry 280,
17657–17663.
Li, G., Boucher, J.C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L.,
Beatty, N., Abate-Daga, D., et al. (2018). 4-1BB enhancement of CAR T function
requires NF-κB and TRAFs. JCI Insight 3, 1999.
Li, W., Fan, D., Yang, M., Yan, Y., Shi, R., Cheng, J., Li, Z., Zhang, M., Wang, J., and
Xiong, D. (2013). Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia
cells mediated by bispecific antibody. Human Gene Therapy 24, 751–760.
Li, Y., Wang, H., Zhou, X., Xie, X., Chen, X., Jie, Z., Zou, Q., Hu, H., Zhu, L., Cheng,
X., et al. (2016). Cell intrinsic role of NF-κB-inducing kinase in regulating T cellmediated immune and autoimmune responses. Sci Rep 6, 22115.
Li, Y., Zhou, Q.-L., Sun, W., Chandrasekharan, P., Cheng, H.S., Ying, Z., Lakshmanan,
M., Raju, A., Tenen, D.G., Cheng, S.-Y., et al. (2015). Non-canonical NF-κB signalling
and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat. Cell Biol.
17, 1327–1338.
Li, Y., Sedwick, C.E., Hu, J., and Altman, A. (2005). Role for protein kinase Ctheta
(PKCtheta) in TCR/CD28-mediated signaling through the canonical but not the noncanonical pathway for NF-kappaB activation. J. Biol. Chem. 280, 1217–1223.
Liao, G., Zhang, M., Harhaj, E.W., and Sun, S.-C. (2004). Regulation of the NF-kappaBinducing kinase by tumor necrosis factor receptor-associated factor 3-induced
degradation. J. Biol. Chem. 279, 26243–26250.
Ling, L., Cao, Z., and Goeddel, D.V. (1998). NF-kappaB-inducing kinase activates IKKalpha by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. U.S.a. 95, 3792–3797.
112

Liu, H., Rhodes, M., Wiest, D.L., and Vignali, D.A. (2000). On the dynamics of
TCR:CD3 complex cell surface expression and downmodulation. Immunity 13, 665–675.
Liu, J., Sudom, A., Min, X., Cao, Z., Gao, X., Ayres, M., Lee, F., Cao, P., Johnstone, S.,
Plotnikova, O., et al. (2012). Structure of the nuclear factor κB-inducing kinase (NIK)
kinase domain reveals a constitutively active conformation. Journal of Biological
Chemistry 287, 27326–27334.
Liu, X., Berry, C.T., Ruthel, G., Madara, J.J., MacGillivray, K., Gray, C.M., Madge,
L.A., McCorkell, K.A., Beiting, D.P., Hershberg, U., et al. (2016). T Cell Receptorinduced Nuclear Factor κB (NF-κB) Signaling and Transcriptional Activation Are
Regulated by STIM1- and Orai1-mediated Calcium Entry. J. Biol. Chem. 291, 8440–
8452.
Liu, Z., Mar, K.B., Hanners, N.W., Perelman, S.S., Kanchwala, M., Xing, C., Schoggins,
J.W., and Alto, N.M. (2019). A NIK-SIX signalling axis controls inflammation by
targeted silencing of non-canonical NF-κB. Nature 22, 1.
Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M.,
Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. (2015). 4-1BB
costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric
antigen receptors. Nat Med 21, 581–590.
Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser, J.L., and Rosenberg, S.A. (1981).
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell
growth factor. Cancer Research 41, 4420–4425.
Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., and Auberger,
P. (2003). Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation
via the proteasome pathway and regulates its proapoptotic function. Oncogene 22, 6785–
6793.
Ludwinski, M.W., Sun, J., Hilliard, B., Gong, S., Xue, F., Carmody, R.J., Devirgiliis, J.,
and Chen, Y.H. (2009). Critical roles of Bim in T cell activation and T cell-mediated
autoimmune inflammation in mice. J. Clin. Invest. 119, 1706–1713.
Luftig, M., Yasui, T., Soni, V., Kang, M.-S., Jacobson, N., Cahir-McFarland, E., Seed,
B., and Kieff, E. (2004). Epstein-Barr virus latent infection membrane protein 1 TRAFbinding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation.
Proc. Natl. Acad. Sci. U.S.a. 101, 141–146.
MacIver, N.J., Michalek, R.D., and Rathmell, J.C. (2013). Metabolic Regulation of T
Lymphocytes. Annu. Rev. Immunol. 31, 259–283.

113

Madge, L.A., and May, M.J. (2009). Inhibiting Proinflammatory NF-κB Signaling Using
Cell-Penetrating NEMO Binding Domain Peptides. In Inflammation and Cancer,
(Humana Press), pp. 209–232.
Maher, J., Brentjens, R.J., Gunset, G., Riviere, I., and Sadelain, M. (2002). Human Tlymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28
receptor. Nat. Biotechnol. 20, 70–75.
Majzner, R.G., and Mackall, C.L. (2019). Clinical lessons learned from the first leg of the
CAR T cell journey. Nat Med 25, 1341–1355.
Majzner, R.G., Rietberg, S.P., Labanieh, L., Sotillo, E., Weber, E.W., Lynn, R.C.,
Theruvath, J.L., Yuan, C.M., Xu, P., Nguyen, S.M., et al. (2018). Low CD19 Antigen
Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational
Redesign of CAR Signaling Domains. Blood 132.
Malinin, N.L., Boldin, M.P., Kovalenko, A.V., and Wallach, D. (1997). MAP3K-related
kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385, 540–544.
Mamonkin, M., Mukherjee, M., Srinivasan, M., Sharma, S., Gomes-Silva, D., Mo, F.,
Krenciute, G., Orange, J.S., and Brenner, M.K. (2017). Reversible Transgene Expression
Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-Cell
Malignancies. Cancer Immunol Res canimm.0126.2017.
Marinari, B., Costanzo, A., Marzano, V., Piccolella, E., and Tuosto, L. (2004). CD28
delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB
subunits on IL-8 and Bcl-xL gene promoters. Proc. Natl. Acad. Sci. U.S.a. 101, 6098–
6103.
Martinez-Forero, I., Azpilikueta, A., Bolaños-Mateo, E., Nistal-Villan, E., Palazon, A.,
Teijeira, A., Perez-Chacon, G., Morales-Kastresana, A., Murillo, O., Jure-Kunkel, M., et
al. (2013). T cell costimulation with anti-CD137 monoclonal antibodies is mediated by
K63-polyubiquitin-dependent signals from endosomes. J. Immunol. 190, 6694–6706.
Masson, F., Kupresanin, F., Mount, A., Strasser, A., and Belz, G.T. (2011). Bid and Bim
collaborate during induction of T cell death in persistent infection. J. Immunol. 186,
4059–4066.
Matsumoto, N., Kojima, S., Osawa, T., and Toyoshima, S. (1995). Protein kinase C
phosphorylates p50 LSP1 and induces translocation of p50 LSP1 in T lymphocytes. J.
Biochem. 117, 222–229.
Maude, S., and Barrett, D.M. (2016). Current status of chimeric antigen receptor therapy
for haematological malignancies. Br. J. Haematol. 172, 11–22.

114

Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A.,
Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. (2014). Chimeric antigen receptor T cells
for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517.
Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader,
P., Verneris, M.R., Stefanski, H.E., Myers, G.D., et al. (2018). Tisagenlecleucel in
Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378,
439–448.
McArthur, K., Whitehead, L.W., Heddleston, J.M., Li, L., Padman, B.S., Oorschot, V.,
Geoghegan, N.D., Chappaz, S., Davidson, S., San Chin, H., et al. (2018). BAK/BAX
macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis.
Science 359, eaao6047.
McPherson, A.J., Snell, L.M., Mak, T.W., and Watts, T.H. (2012). Opposing roles for
TRAF1 in the alternative versus classical NF-κB pathway in T cells. Journal of
Biological Chemistry 287, 23010–23019.
Menk, A.V., Scharping, N.E., Rivadeneira, D.B., Calderon, M.J., Watson, M.J.,
Dunstane, D., Watkins, S.C., and Delgoffe, G.M. (2018). 4-1BB costimulation induces T
cell mitochondrial function and biogenesis enabling cancer immunotherapeutic
responses. Journal of Experimental Medicine 215, jem.20171068–jem.20171100.
Michie, J., Beavis, P.A., Freeman, A.J., Vervoort, S.J., Ramsbottom, K.M., Narasimhan,
V., Lelliott, E.J., Lalaoui, N., Ramsay, R.G., Johnstone, R.W., et al. (2019). Antagonism
of IAPs Enhances CAR T-cell Efficacy. Cancer Immunol Res 7, 183–192.
Miller, A.D., and Rosman, G.J. (1989). Improved retroviral vectors for gene transfer and
expression. BioTechniques 7, 980–2–984–6–989–90.
Milone, M.C., Fish, J.D., Carpenito, C., Carroll, R.G., Binder, G.K., Teachey, D.,
Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009). Chimeric
receptors containing CD137 signal transduction domains mediate enhanced survival of T
cells and increased antileukemic efficacy in vivo. Mol Ther 17, 1453–1464.
Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z.,
Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M., et al. (2013). Cancer regression
and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother.
36, 133–151.
Moritz, D., Wels, W., Mattern, J., and Groner, B. (1994). Cytotoxic T lymphocytes with a
grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci.
U.S.a. 91, 4318–4322.
Mouhamad, S., Besnault, L., Auffredou, M.T., Leprince, C., Bourgeade, M.F., Leca, G.,
and Vazquez, A. (2004). B cell receptor-mediated apoptosis of human lymphocytes is
115

associated with a new regulatory pathway of Bim isoform expression. The Journal of
Immunology 172, 2084–2091.
Mueller, K.T., Maude, S.L., Porter, D.L., Frey, N., Wood, P., Han, X., Waldron, E.,
Chakraborty, A., Awasthi, R., Levine, B.L., et al. (2017). Cellular kinetics of CTL019 in
relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic
leukemia. Blood 130, 2317–2325.
Mueller, K.T., Waldron, E., Grupp, S.A., Levine, J.E., Laetsch, T.W., Pulsipher, M.A.,
Boyer, M.W., August, K.J., Hamilton, J., Awasthi, R., et al. (2018). Clinical
Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clinical
Cancer Research.
Mukherjee, T., Chatterjee, B., Dhar, A., Bais, S.S., Chawla, M., Roy, P., George, A., Bal,
V., Rath, S., and Basak, S. (2017). A TNF-p100 pathway subverts noncanonical NF-κB
signaling in inflamed secondary lymphoid organs. The EMBO Journal e201796919.
Murray, S.E., Polesso, F., Rowe, A.M., Basak, S., Koguchi, Y., Toren, K.G., Hoffmann,
A., and Parker, D.C. (2011). NF-κB–inducing kinase plays an essential T cell–intrinsic
role in graft-versus-host disease and lethal autoimmunity in mice. J. Clin. Invest. 121,
4775–4786.
Müller, J.R., and Siebenlist, U. (2003). Lymphotoxin beta receptor induces sequential
activation of distinct NF-kappa B factors via separate signaling pathways. J. Biol. Chem.
278, 12006–12012.
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., and
Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a
lentiviral vector. Science 272, 263–267.
Neelapu, S.S., Locke, F.L., Bartlett, N.L., Lekakis, L.J., Miklos, D.B., Jacobson, C.A.,
Braunschweig, I., Oluwole, O.O., Siddiqi, T., Lin, Y., et al. (2017). Axicabtagene
Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med.
377, 2531–2544.
O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M., Cory, S., and
Huang, D.C. (1998). Bim: a novel member of the Bcl-2 family that promotes apoptosis.
The EMBO Journal 17, 384–395.
O'Leary, M.C., Lu, X., Huang, Y., Lin, X., Mahmood, I., Przepiorka, D., Gavin, D., Lee,
S., Liu, K., George, B., et al. (2019). FDA Approval Summary: Tisagenlecleucel for
Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic
Leukemia. Clinical Cancer Research 25, 1142–1146.
O'Reilly, L.A., Kruse, E.A., Puthalakath, H., Kelly, P.N., Kaufmann, T., Huang, D.C.S.,
and Strasser, A. (2009). MEK/ERK-mediated phosphorylation of Bim is required to
116

ensure survival of T and B lymphocytes during mitogenic stimulation. J. Immunol. 183,
261–269.
Orlando, E.J., Han, X., Tribouley, C., Wood, P.A., Leary, R.J., Riester, M., Levine, J.E.,
Qayed, M., Grupp, S.A., Boyer, M., et al. (2018). Genetic mechanisms of target antigen
loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24, 1504–1506.
Oussa, N.A.E., Soumounou, Y., and Sabbagh, L. (2013). TRAF1 phosphorylation on
Serine 139 modulates NF-κB activity downstream of 4-1BB in T cells. Biochem.
Biophys. Res. Commun. 432, 129–134.
Pagès, F., Ragueneau, M., Rottapel, R., Truneh, A., Nunes, J., Imbert, J., and Olive, D.
(1994). Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell
signalling. Nature 369, 327–329.
Park, J.R., Digiusto, D.L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet,
H.B., Bautista, C., Chang, W.-C., Ostberg, J.R., et al. (2007). Adoptive transfer of
chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with
neuroblastoma. Mol Ther 15, 825–833.
Paul, A., Edwards, J., Pepper, C., and Mackay, S. (2018). Inhibitory-κB Kinase (IKK) α
and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.
Cells 7, 176.
Payne, A.S., Hanakawa, Y., Amagai, M., and Stanley, J.R. (2004). Desmosomes and
disease: pemphigus and bullous impetigo. Curr. Opin. Cell Biol. 16, 536–543.
Pearce, E.L., Walsh, M.C., Cejas, P.J., Harms, G.M., Shen, H., Wang, L.-S., Jones, R.G.,
and Choi, Y. (2009). Enhancing CD8 T-cell memory by modulating fatty acid
metabolism. Nature 460, 103–107.
Pitcher, L.A., and van Oers, N.S.C. (2003). T-cell receptor signal transmission: who
gives an ITAM? Trends in Immunology 24, 554–560.
Pollok, K.E., Kim, Y.J., Zhou, Z., Hurtado, J., Kim, K.K., Pickard, R.T., and Kwon, B.S.
(1993). Inducible T cell antigen 4-1BB. Analysis of expression and function. The Journal
of Immunology 150, 771–781.
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., and June, C.H. (2011). Chimeric antigen
receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733.
Prasad, K.V., Cai, Y.C., Raab, M., Duckworth, B., Cantley, L., Shoelson, S.E., and Rudd,
C.E. (1994). T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl. Acad. Sci. U.S.a. 91,
2834–2838.
117

Priceman, S.J., Gerdts, E.A., Tilakawardane, D., Kennewick, K.T., Murad, J.P., Park,
A.K., Jeang, B., Yamaguchi, Y., Yang, X., Urak, R., et al. (2018). Co-stimulatory
signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting
PSCA+ metastatic prostate cancer. Oncoimmunology 7, e1380764.
Puthalakath, H., and Strasser, A. (2002). Keeping killers on a tight leash: transcriptional
and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell
Death Differ. 9, 505–512.
Puthalakath, H., Huang, D.C., O'Reilly, L.A., King, S.M., and Strasser, A. (1999). The
proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the
dynein motor complex. Mol. Cell 3, 287–296.
Ramakrishnan, P., Wang, W., and Wallach, D. (2004). Receptor-specific signaling for
both the alternative and the canonical NF-kappaB activation pathways by NF-kappaBinducing kinase. Immunity 21, 477–489.
Ramello, M.C., Benzaïd, I., Kuenzi, B.M., Lienlaf-Moreno, M., Kandell, W.M.,
Santiago, D.N., Pabón-Saldaña, M., Darville, L., Fang, B., Rix, U., et al. (2019). An
immunoproteomic approach to characterize the CAR interactome and signalosome. Sci
Signal 12, eaap9777.
Ramos, C.A., Rouce, R., Robertson, C.S., Reyna, A., Narala, N., Vyas, G., Mehta, B.,
Zhang, H., Dakhova, O., Carrum, G., et al. (2018). In Vivo Fate and Activity of Secondversus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's
Lymphomas. Mol Ther.
Ramos, C.A., Savoldo, B., and Dotti, G. (2014). CD19-CAR trials. Cancer J 20, 112–118.
Ranuncolo, S.M., Pittaluga, S., Evbuomwan, M.O., Jaffe, E.S., and Lewis, B.A. (2012).
Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for
survival. Blood 120, 3756–3763.
Rehe, K., Wilson, K., Bomken, S., Williamson, D., Irving, J., Boer, den, M.L., Stanulla,
M., Schrappe, M., Hall, A.G., Heidenreich, O., et al. (2013). Acute B lymphoblastic
leukaemia-propagating cells are present at high frequency in diverse lymphoblast
populations. EMBO Mol Med 5, 38–51.
Remouchamps, C., and Dejardin, E. (2015). Methods to assess the activation of the
alternative (noncanonical) NF-κB pathway by non-death TNF receptors. Methods Mol.
Biol. 1280, 103–119.
Riou, C., Yassine-Diab, B., Van grevenynghe, J., Somogyi, R., Greller, L.D., Gagnon,
D., Gimmig, S., Wilkinson, P., Shi, Y., Cameron, M.J., et al. (2007). Convergence of
TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of
CD4+ central memory T cells. J. Exp. Med. 204, 79–91.
118

Romeo, C., and Seed, B. (1991). Cellular immunity to HIV activated by CD4 fused to T
cell or Fc receptor polypeptides. Cell 64, 1037–1046.
Rosenberg, S.A. (1999). A new era for cancer immunotherapy based on the genes that
encode cancer antigens. Immunity 10, 281–287.
Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E.,
Matory, Y.L., Skibber, J.M., Shiloni, E., and Vetto, J.T. (1985). Observations on the
systemic administration of autologous lymphokine-activated killer cells and recombinant
interleukin-2 to patients with metastatic cancer. N Engl J Med 313, 1485–1492.
Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T.,
Simon, P., Lotze, M.T., Yang, J.C., and Seipp, C.A. (1988). Use of tumor-infiltrating
lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic
melanoma. A preliminary report. N Engl J Med 319, 1676–1680.
Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q.,
Citrin, D.E., Restifo, N.P., Robbins, P.F., Wunderlich, J.R., et al. (2011). Durable
complete responses in heavily pretreated patients with metastatic melanoma using T-cell
transfer immunotherapy. Clinical Cancer Research 17, 4550–4557.
Rowe, A.M., Murray, S.E., Raué, H.-P., Koguchi, Y., Slifka, M.K., and Parker, D.C.
(2013). A cell-intrinsic requirement for NF-κB-inducing kinase in CD4 and CD8 T cell
memory. J. Immunol. 191, 3663–3672.
Rudd, C.E., Taylor, A., and Schneider, H. (2009). CD28 and CTLA-4 coreceptor
expression and signal transduction. Immunological Reviews 229, 12–26.
Sabbagh, L., Andreeva, D., Laramée, G.D., Oussa, N.A.E., Lew, D., Bisson, N.,
Soumounou, Y., Pawson, T., and Watts, T.H. (2013). Leukocyte-specific protein 1 links
TNF receptor-associated factor 1 to survival signaling downstream of 4-1BB in T cells.
Journal of Leukocyte Biology 93, 713–721.
Sabbagh, L., Pulle, G., Liu, Y., Tsitsikov, E.N., and Watts, T.H. (2008). ERK-dependent
Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of
CD8 T cell survival in vivo. The Journal of Immunology 180, 8093–8101.
Sachdeva, M., Duchateau, P., Depil, S., Poirot, L., and Valton, J. (2019). Granulocytemacrophage colony-stimulating factor inactivation in CAR T-cells prevents monocytedependent release of key cytokine release syndrome mediators. J. Biol. Chem. 294,
5430–5437.
Sallusto, F., Geginat, J., and Lanzavecchia, A. (2004). Central memory and effector
memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22,
745–763.
119

Salojin, K.V., Zhang, J., and Delovitch, T.L. (1999). TCR and CD28 are coupled via
ZAP-70 to the activation of the Vav/Rac-1-/PAK-1/p38 MAPK signaling pathway. The
Journal of Immunology 163, 844–853.
Salter, A.I., Ivey, R.G., Kennedy, J.J., Voillet, V., Rajan, A., Alderman, E.J., Voytovich,
U.J., Lin, C., Sommermeyer, D., Liu, L., et al. (2018). Phosphoproteomic analysis of
chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect
cell function. Sci Signal 11, eaat6753.
Sanchez-Paulete, A.R., Labiano, S., Rodriguez-Ruiz, M.E., Azpilikueta, A., Etxeberria,
I., Bolaños, E., Lang, V., Rodriguez, M., Aznar, M.A., Jure-Kunkel, M., et al. (2016).
Deciphering cd137 (4-1bb) signaling in T-cell costimulation for translation into
successful cancer immunotherapy. Eur. J. Immunol. n/a–n/a.
Saoulli, K., Lee, S.Y., Cannons, J.L., Yeh, W.C., Santana, A., Goldstein, M.D., Bangia,
N., DeBenedette, M.A., Mak, T.W., Choi, Y., et al. (1998). CD28-independent, TRAF2dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187, 1849–
1862.
Schimmack, G., Eitelhuber, A.C., Vincendeau, M., Demski, K., Shinohara, H., Kurosaki,
T., and Krappmann, D. (2014). AIP augments CARMA1-BCL10-MALT1 complex
formation to facilitate NF-κB signaling upon T cell activation. Cell Commun. Signal 12,
49.
Schneider, H., Cai, Y.C., Prasad, K.V., Shoelson, S.E., and Rudd, C.E. (1995). T cell
antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras. Eur. J. Immunol.
25, 1044–1050.
Schwartz, R.H. (1985). T-lymphocyte recognition of antigen in association with gene
products of the major histocompatibility complex. Annu. Rev. Immunol. 3, 237–261.
Senftleben, U., Cao, Y., Xiao, G., Greten, F.R., Krähn, G., Bonizzi, G., Chen, Y., Hu, Y.,
Fong, A., Sun, S.C., et al. (2001). Activation by IKKalpha of a second, evolutionary
conserved, NF-kappa B signaling pathway. Science 293, 1495–1499.
Shinkura, R., Kitada, K., Matsuda, F., Tashiro, K., Ikuta, K., Suzuki, M., Kogishi, K.,
Serikawa, T., and Honjo, T. (1999). Alymphoplasia is caused by a point mutation in the
mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 22, 74–77.
Shinzawa, M., Konno, H., Qin, J., Akiyama, N., Miyauchi, M., Ohashi, H., MiyamotoSato, E., Yanagawa, H., Akiyama, T., and Inoue, J.-I. (2015). Catalytic subunits of the
phosphatase calcineurin interact with NF-κB-inducing kinase (NIK) and attenuate NIKdependent gene expression. Sci Rep 5, 10758.
Shuford, W.W., Klussman, K., Tritchler, D.D., Loo, D.T., Chalupny, J., Siadak, A.W.,
Brown, T.J., Emswiler, J., Raecho, H., Larsen, C.P., et al. (1997). 4-1BB costimulatory
120

signals preferentially induce CD8+ T cell proliferation and lead to the amplification in
vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47–55.
Smith, C.A., Davis, T., Anderson, D., Solam, L., Beckmann, M.P., Jerzy, R., Dower,
S.K., Cosman, D., and Goodwin, R.G. (1990). A receptor for tumor necrosis factor
defines an unusual family of cellular and viral proteins. Science 248, 1019–1023.
Smith, L., and Venella, K. (2017). Cytokine Release Syndrome: Inpatient Care for Side
Effects of CAR T-Cell Therapy
. Clin J Oncol Nurs 21, 29–34.
Smith-Garvin, J.E., Koretzky, G.A., and Jordan, M.S. (2009). T cell activation. Annu.
Rev. Immunol. 27, 591–619.
Snell, L.M., Lin, G.H.Y., McPherson, A.J., Moraes, T.J., and Watts, T.H. (2011). T-cell
intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Immunological Reviews 244, 197–217.
Snow, P.M., and Terhorst, C. (1983). The T8 antigen is a multimeric complex of two
distinct subunits on human thymocytes but consists of homomultimeric forms on
peripheral blood T lymphocytes. Journal of Biological Chemistry 258, 14675–14681.
Sommermeyer, D., Hudecek, M., Kosasih, P.L., Gogishvili, T., Maloney, D.G., Turtle,
C.J., and Riddell, S.R. (2016). Chimeric antigen receptor-modified T cells derived from
defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia
30, 492–500.
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June,
C.H., Coukos, G., and Powell, D.J. (2011). In vivo persistence, tumor localization, and
antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling
through CD137 (4-1BB). Cancer Research 71, 4617–4627.
Soroosh, P., Ine, S., Sugamura, K., and Ishii, N. (2006). OX40-OX40 ligand interaction
through T cell-T cell contact contributes to CD4 T cell longevity. The Journal of
Immunology 176, 5975–5987.
Stadanlick, J.E., Kaileh, M., Karnell, F.G., Scholz, J.L., Miller, J.P., Quinn, W.J.I.,
Brezski, R.J., Treml, L.S., Jordan, K.A., Monroe, J.G., et al. (2008). Tonic B cell antigen
receptor signals supply an NF-kappa B substrate for prosurvival BLyS signaling. Nat.
Immunol. 9, 1379–1387.
Stancovski, I., Schindler, D.G., Waks, T., Yarden, Y., Sela, M., and Eshhar, Z. (1993).
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain
Fv receptors. The Journal of Immunology 151, 6577–6582.
121

Stärck, L., Scholz, C., Dörken, B., and Daniel, P.T. (2005). Costimulation by CD137/41BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via
phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur. J. Immunol. 35, 1257–
1266.
Sterner, R.M., Sakemura, R., Cox, M.J., Yang, N., Khadka, R.H., Forsman, C.L., Hansen,
M.J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2019). GM-CSF inhibition reduces cytokine
release syndrome and neuroinflammation but enhances CAR-T cell function in
xenografts. Blood 133, 697–709.
Sun, S.C., Ganchi, P.A., Béraud, C., Ballard, D.W., and Greene, W.C. (1994).
Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic
inhibitors containing ankyrin motifs. Proc. Natl. Acad. Sci. U.S.a. 91, 1346–1350.
Sun, S.-C. (2012). The noncanonical NF-κB pathway. Immunological Reviews 246, 125–
140.
Sun, S.-C. (2017). The non-canonical NF-κB pathway in immunity and inflammation.
Nat. Rev. Immunol. 17, 545–558.
Sun, Z., Arendt, C.W., Ellmeier, W., Schaeffer, E.M., Sunshine, M.J., Gandhi, L., Annes,
J., Petrzilka, D., Kupfer, A., Schwartzberg, P.L., et al. (2000). PKC-theta is required for
TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature
404, 402–407.
Sunters, A., Fernández de Mattos, S., Stahl, M., Brosens, J.J., Zoumpoulidou, G.,
Saunders, C.A., Coffer, P.J., Medema, R.H., Coombes, R.C., and Lam, E.W.-F. (2003).
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast
cancer cell lines. Journal of Biological Chemistry 278, 49795–49805.
Takaori-Kondo, A., Hori, T., Fukunaga, K., Morita, R., Kawamata, S., and Uchiyama, T.
(2000). Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NFkappaB activation induced by OX40 signaling. Biochem. Biophys. Res. Commun. 272,
856–863.
Takasawa, N., Ishii, N., Higashimura, N., Murata, K., Tanaka, Y., Nakamura, M., Sasaki,
T., and Sugamura, K. (2001). Expression of gp34 (OX40 Ligand) and OX40 on Human T
Cell Clones. Japanese Journal of Cancer Research 92, 377–382.
Tan, P., Anasetti, C., Hansen, J.A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter,
J.A., and Linsley, P.S. (1993). Induction of alloantigen-specific hyporesponsiveness in
human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J.
Exp. Med. 177, 165–173.

122

Tchoghandjian, A., Jennewein, C., Eckhardt, I., Rajalingam, K., and Fulda, S. (2013).
Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimeticstimulated migration and invasion of glioblastoma cells. Cell Death Dis 4, e564.
Thomas, E.D., Storb, R., Clift, R.A., Fefer, A., Johnson, L., Neiman, P.E., Lerner, K.G.,
Glucksberg, H., and Buckner, C.D. (1975). Bone-marrow transplantation (second of two
parts). N Engl J Med 292, 895–902.
Thomas, R.M., Gao, L., and Wells, A.D. (2005). Signals from CD28 induce stable
epigenetic modification of the IL-2 promoter. The Journal of Immunology 174, 4639–
4646.
Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X.,
James, S.E., Raubitschek, A., Forman, S.J., et al. (2008). Adoptive immunotherapy for
indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified
autologous CD20-specific T cells. Blood 112, 2261–2271.
Tone, Y., Kojima, Y., Furuuchi, K., Brady, M., Yashiro-Ohtani, Y., Tykocinski, M.L.,
and Tone, M. (2007). OX40 gene expression is up-regulated by chromatin remodeling in
its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. The Journal
of Immunology 179, 1760–1767.
Topalian, S.L., Muul, L.M., Solomon, D., and Rosenberg, S.A. (1987). Expansion of
human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol.
Methods 102, 127–141.
Turtle, C.J., Hanafi, L.-A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M.,
Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. (2016). CD19 CAR-T
cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients. J. Clin.
Invest. 126, 2123–2138.
Uno, M., Saitoh, Y., Mochida, K., Tsuruyama, E., Kiyono, T., Imoto, I., Inazawa, J.,
Yuasa, Y., Kubota, T., and Yamaoka, S. (2014). NF-κB inducing kinase, a central
signaling component of the non-canonical pathway of NF-κB, contributes to ovarian
cancer progression. PLoS ONE 9, e88347.
Valiño-Rivas, L., Gonzalez-Lafuente, L., Sanz, A.B., Ruiz-Ortega, M., Ortiz, A., and
Sanchez-Niño, M.D. (2016). Non-canonical NFκB activation promotes chemokine
expression in podocytes. Sci Rep 6, 28857.
Vallabhapurapu, S., and Karin, M. (2009). Regulation and function of NF-kappaB
transcription factors in the immune system. Annu. Rev. Immunol. 27, 693–733.
Vallabhapurapu, S., Matsuzawa, A., Zhang, W., Tseng, P.-H., Keats, J.J., Wang, H.,
Vignali, D.A.A., Bergsagel, P.L., and Karin, M. (2008). Nonredundant and
complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that
123

activates NIK-dependent alternative NF-kappaB signaling. Nature Publishing Group 9,
1364–1370.
Vallabhapurapu, S.D., Noothi, S.K., Pullum, D.A., Lawrie, C.H., Pallapati, R., Potluri,
V., Kuntzen, C., Khan, S., Plas, D.R., Orlowski, R.Z., et al. (2015). Transcriptional
repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and
growth. Nature Communications 6, 8428.
van der Stegen, S.J.C., Hamieh, M., and Sadelain, M. (2015). The pharmacology of
second-generation chimeric antigen receptors. Nat Rev Drug Discov 14, 499–509.
van der Windt, G.J.W., Everts, B., Chang, C.-H., Curtis, J.D., Freitas, T.C., Amiel, E.,
Pearce, E.J., and Pearce, E.L. (2012). Mitochondrial respiratory capacity is a critical
regulator of CD8+ T cell memory development. Immunity 36, 68–78.
van der Windt, G.J.W., O’Sullivan, D., Everts, B., Huang, S.C.-C., Buck, M.D., Curtis,
J.D., Chang, C.-H., Smith, A.M., Ai, T., Faubert, B., et al. (2013). CD8 memory T cells
have a bioenergetic advantage that underlies their rapid recall ability. Proceedings of the
National Academy of Sciences 110, 14336–14341.
Walker, A.J., Majzner, R.G., Zhang, L., Wanhainen, K., Long, A.H., Nguyen, S.M.,
Lopomo, P., Vigny, M., Fry, T.J., Orentas, R.J., et al. (2017). Tumor Antigen and
Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting
Anaplastic Lymphoma Kinase. Mol Ther 25, 2189–2201.
Wang, C., Lin, G.H.Y., McPherson, A.J., and Watts, T.H. (2009). Immune regulation by
4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews 229, 192–215.
Wang, E., Wang, L.-C., Tsai, C.-Y., Bhoj, V., Gershenson, Z., Moon, E., Newick, K.,
Sun, J., Lo, A., Baradet, T., et al. (2015). Generation of Potent T-cell Immunotherapy for
Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol
Res 3, 815–826.
Wang, Z., Zhang, B., Yang, L., Ding, J., and Ding, H.-F. (2008). Constitutive production
of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory
autoimmune disease by repressing Bim expression. Journal of Biological Chemistry 283,
10698–10706.
Weinkove, R., George, P., Dasyam, N., and McLellan, A.D. (2019). Selecting
costimulatory domains for chimeric antigen receptors: functional and clinical
considerations. Clin Transl Immunology 8, e1049.
Wharry, C.E., Haines, K.M., Carroll, R.G., and May, M.J. (2009). Constitutive noncanonical NFkappaB signaling in pancreatic cancer cells. Cancer Biol. Ther. 8, 1567–
1576.
124

Willmann, K.L., Klaver, S., Doğu, F., Santos-Valente, E., Garncarz, W., Bilic, I., Mace,
E., Salzer, E., Conde, C.D., Sic, H., et al. (2014). Biallelic loss-of-function mutation in
NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.
Nature Communications 5, 5360.
Woglom, W.H. (1929). Immunity to Transplantable Tumours. Cancer Review 4, 129–
214.
Wojciechowski, S., Jordan, M.B., Zhu, Y., White, J., Zajac, A.J., and Hildeman, D.A.
(2006). Bim mediates apoptosis of CD127lo effector T cells and limits T cell memory.
Eur. J. Immunol. 36, 1694–1706.
Won, E.-Y., Cha, K., Byun, J.-S., Kim, D.-U., Shin, S., Ahn, B., Kim, Y.H., Rice, A.J.,
Walz, T., Kwon, B.S., et al. (2010). The structure of the trimer of human 4-1BB ligand is
unique among members of the tumor necrosis factor superfamily. J. Biol. Chem. 285,
9202–9210.
Wu, J.-L., Wu, H.-Y., Tsai, D.-Y., Chiang, M.-F., Chen, Y.-J., Gao, S., Lin, C.-C., Lin,
C.-H., Khoo, K.-H., Chen, Y.-J., et al. (2016). Temporal regulation of Lsp1 OGlcNAcylation and phosphorylation during apoptosis of activated B cells. Nature
Communications 7, 12526–11.
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A.,
Cinti, S., Lowell, B., Scarpulla, R.C., et al. (1999). Mechanisms controlling
mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1.
Cell 98, 115–124.
Xiao, G., Harhaj, E.W., and Sun, S.C. (2001). NF-kappaB-inducing kinase regulates the
processing of NF-kappaB2 p100. Mol. Cell 7, 401–409.
Xiao, X., Balasubramanian, S., Liu, W., Chu, X., Wang, H., Taparowsky, E.J., Fu, Y.-X.,
Choi, Y., Walsh, M.C., and Li, X.C. (2012). OX40 signaling favors the induction of
T(H)9 cells and airway inflammation. Nature Publishing Group 13, 981–990.
Xiao, X., Shi, X., Fan, Y., Wu, C., Zhang, X., Minze, L., Liu, W., Ghobrial, R.M., Lan,
P., and Li, X.C. (2016). The Costimulatory Receptor OX40 Inhibits Interleukin-17
Expression through Activation of Repressive Chromatin Remodeling Pathways.
Immunity 44, 1271–1283.
Xiu, Y., Dong, Q., Li, Q., Li, F., Borcherding, N., Zhang, W., Boyce, B., Xue, H.-H., and
Zhao, C. (2018). Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced
Acute Myeloid Leukemia. Cell Rep 22, 350–358.
Yang, J., Zhang, S., Zhang, L., Xie, X., Wang, H., Jie, Z., Gu, M., Yang, J.-Y., Cheng,
X., and Sun, S.-C. (2018). Lymphatic endothelial cells regulate B-cell homing to lymph
nodes via a NIK-dependent mechanism. Cell. Mol. Immunol. 84, 830.
125

Yu, J., Zhou, X., Nakaya, M., Jin, W., Cheng, X., and Sun, S.-C. (2014). T cell-intrinsic
function of the noncanonical NF-κB pathway in the regulation of GM-CSF expression
and experimental autoimmune encephalomyelitis pathogenesis. J. Immunol. 193, 422–
430.
Zapata, J.M., Perez-Chacon, G., Carr-Baena, P., Martinez-Forero, I., Azpilikueta, A.,
Otano, I., and Melero, I. (2018). CD137 (4-1BB) Signalosome: Complexity Is a Matter of
TRAFs. Front Immunol 9, 2618.
Zarnegar, B.J., Wang, Y., Mahoney, D.J., Dempsey, P.W., Cheung, H.H., He, J., Shiba,
T., Yang, X., Yeh, W.-C., Mak, T.W., et al. (2008). Noncanonical NF-kappaB activation
requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2,
TRAF2 and TRAF3 and the kinase NIK. Nature Publishing Group 9, 1371–1378.
Zeng, R., Faccio, R., and Novack, D.V. (2015). Alternative NF-κB Regulates RANKLInduced Osteoclast Differentiation and Mitochondrial Biogenesis via Independent
Mechanisms - Zeng - 2015 - Journal of Bone and Mineral Research - Wiley Online
Library. Journal of Bone and Mineral ….
Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M.,
Eshhar, Z., Rosenberg, S.A., and Morgan, R.A. (2009). A herceptin-based chimeric
antigen receptor with modified signaling domains leads to enhanced survival of
transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574.
Zhao, Z., Condomines, M., van der Stegen, S.J.C., Perna, F., Kloss, C.C., Gunset, G.,
Plotkin, J., and Sadelain, M. (2015). Structural Design of Engineered Costimulation
Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell 28,
415–428.
Zheng, C., Kabaleeswaran, V., Wang, Y., Cheng, G., and Wu, H. (2010). Crystal
Structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 Complexes: Affinity,
Specificity, and Regulation. Mol. Cell 38, 101–113.
Zheng, W., O'Hear, C.E., Alli, R., Basham, J.H., Abdelsamed, H.A., Palmer, L.E., Jones,
L.L., Youngblood, B., and Geiger, T.L. (2018). PI3K orchestration of the in vivo
persistence of chimeric antigen receptor-modified T cells. Leukemia 32, 1157–1167.
Zhu, Y., Swanson, B.J., Wang, M., Hildeman, D.A., Schaefer, B.C., Liu, X., Suzuki, H.,
Mihara, K., Kappler, J., and Marrack, P. (2004). Constitutive association of the
proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc.
Natl. Acad. Sci. U.S.a. 101, 7681–7686.

126

